methyl salicylate has been researched along with Hay Fever in 281 studies
methyl salicylate: used in over-the-counter liniments, ointments, lotions for relief of musculoskeletal aches and pains; has hemolytic effect on human & sheep erythrocytes; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5990
methyl salicylate : A benzoate ester that is the methyl ester of salicylic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the effect of montelukast (MK) and SLIT added to standard therapy in moderate asthma over 5 years." | 9.14 | Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. ( Berra, D; Canonica, GW; Chiodini, E; Colombo, F; Marogna, M; Massolo, A; Passalacqua, G; Spadolini, I; Zanon, P, 2010) |
| " We compared the effect of montelukast (MK) and SLIT added to standard therapy in moderate asthma over 5 years." | 5.14 | Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. ( Berra, D; Canonica, GW; Chiodini, E; Colombo, F; Marogna, M; Massolo, A; Passalacqua, G; Spadolini, I; Zanon, P, 2010) |
| "Adults with confirmed birch pollen allergy (n = 253) were randomized to preseasonal placebo (n = 129) or active treatment (n = 124)." | 2.90 | Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension. ( Antila, J; Höiby, AS; Kruse, B; Lipiec, A; Rak, S; Rudert, M; Samoliński, B; Valovirta, E; Worm, M, 2019) |
| "Mild-to-moderate treatment-related adverse events were reported for 57." | 2.90 | Fast up-dosing with a birch allergoid is safe and well tolerated in allergic rhinitis patients with or without asthma. ( Akboga, Y; Plückhahn, K; Rieker-Schwienbacher, J; Rosewich, M; Thieme, U; Zielen, S, 2019) |
| "Sublingual immunotherapy (SLIT) is a potential efficacious and safe treatment option for patients with respiratory, IgE-mediated allergic diseases." | 2.82 | A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. ( Boot, JD; Diamant, Z; Klimek, L; Kuna, P; Opstelten, DJ; Panzner, P; Pfaar, O; van Ree, R; van Twuijver, E, 2016) |
| "The purpose of the study was to examine effects of pre-treatment with a Toll-like receptor 7 (TLR7) agonist (AZD8848) in allergic rhinitis and to evaluate clinical effects of two dosing regimens." | 2.80 | Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study. ( Ahlström-Emanuelsson, C; Alenäs, M; Almqvist, G; Andersson, M; Cervin, A; Dolata, J; Greiff, L; Lindgren, S; Mårtensson, A; Widegren, H; Young, B, 2015) |
| "All patients tolerated the intralymphatic immunotherapy (ILIT) treatment well, and the injections did not elicit any severe adverse event." | 2.78 | Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. ( Cardell, LO; Hylander, T; Latif, L; Petersson-Westin, U, 2013) |
| "Acupuncture is frequently used to treat seasonal allergic rhinitis (SAR) despite limited scientific evidence." | 2.78 | Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. ( Brinkhaus, B; Hummelsberger, J; Linde, K; Niggemann, B; Ortiz, M; Pfab, F; Ring, J; Roll, S; Treszl, A; Wegscheider, K; Willich, SN; Witt, CM; Zuberbier, T, 2013) |
| "Patients with birch pollen allergy (major allergen: Bet v 1) have often an associated oral allergy syndrome (OAS) to apple, which contains the cross-reactive allergen Mal d 1." | 2.77 | Continuous apple consumption induces oral tolerance in birch-pollen-associated apple allergy. ( Gentinetta, T; Gerber, R; Hausmann, O; Kopac, P; Pichler, Ch; Pichler, WJ; Rudin, M; Schnyder, B, 2012) |
| "To investigate whether birch pollen allergy symptoms are linked with gut microbiota changes and whether probiotics have an effect on these." | 2.74 | Specific probiotics alleviate allergic rhinitis during the birch pollen season. ( Collado, MC; Isolauri, E; Nermes, M; Ouwehand, AC; Rautonen, N; Salminen, S, 2009) |
| "The significant improvement in hay fever and CPT results observed after 3 years of SIT persisted at the 5-year follow-up." | 2.72 | Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. ( Dreborg, S; Ferdousi, HA; Halken, S; Høst, A; Jacobsen, L; Koivikko, A; Koller, D; Möller, C; Niggemann, B; Norberg, LA; Urbanek, R; Valovirta, E; Wahn, U, 2006) |
| " This study investigated the clinical efficacy, safety and dose-response relationship of SLIT in children suffering from rhinoconjunctivitis with/without asthma." | 2.72 | Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. ( Jacobsen, L; Koivikko, A; Ljørring, C; Savolainen, J; Valovirta, E, 2006) |
| "Desloratadine (5 mg) was administered orally once daily for 5 days in a placebo-controlled, crossover design to 24 patients with allergic rhinitis." | 2.70 | Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. ( Andersson, M; Greiff, L; Persson, CG, 2002) |
| "High-dose, subcutaneous IT is efficacious and safe in patients with severe birch pollen rhinoconjunctivitis and asthma." | 2.70 | The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. ( Bødtger, U; Jacobi, HH; Malling, HJ; Poulsen, LK, 2002) |
| "All subjects had moderate to severe hay fever symptoms, but at inclusion none reported asthma with need of daily treatment." | 2.70 | Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). ( Dreborg, S; Ferdousi, HA; Halken, S; Høst, A; Jacobsen, L; Koivikko, A; Koller, DY; Möller, C; Niggemann, B; Norberg, LA; Urbanek, R; Valovirta, E; Wahn, U, 2002) |
| "The frequency of OAS with pollen allergy has been reported as 5-8%; 1-2% of patients with OAS with pollen allergy show extreme responses, e." | 2.58 | Oral allergy syndrome. ( Cingi, C; Muluk, NB, 2018) |
| "Data about the rate of sensitization and food allergy are available." | 2.41 | Food allergy and IgE sensitization caused by spices: CICBAA data (based on 589 cases of food allergy). ( Croizier, A; Kanny, G; Lemerdy, P; Moneret-Vautrin, DA; Morisset, M, 2002) |
| "All subjects had confirmed allergy to birch and self-reported physician-diagnosed asthma." | 1.72 | Birch pollen, air pollution and their interactive effects on airway symptoms and peak expiratory flow in allergic asthma during pollen season - a panel study in Northern and Southern Sweden. ( Behndig, AF; Carlsen, HK; Forsberg, B; Haga, SL; Meister, K; Modig, L; Olin, AC; Olsson, D, 2022) |
| "The concomitant pollinosis significantly increased the risk of SPT reaction to all tested herbs in adults (odds ratio, OR = 2." | 1.72 | Higher Risk for Sensitization to Commonly Consumed Herbs among Adults and Youngsters Suffering from Birch, Mugwort or Grass Pollinosis. ( Buczyłko, K; Stasiak, A; Szwed-Kowalska, A; Wagner, A; Wagner, W, 2022) |
| "Primary hazelnut allergy is a common cause of anaphylaxis in children, as compared to birch-pollen associated hazelnut allergy." | 1.62 | Primary and pollen-associated hazelnut allergy in school-aged children in Germany: A birth cohort study. ( Bellach, J; Beyer, K; Erhard, SM; Fernandez-Rivas, M; Grabenhenrich, LB; Keil, T; Trendelenburg, V; Tschirner, S; van Ree, R; Yürek, S, 2021) |
| " Mild, local, treatment-emergent adverse events were noted throughout the course of treatment but resolved spontaneously." | 1.62 | Case Report: Safe and Effective Sublingual Birch Allergen Immunotherapy in Two HIV-Positive Patients. ( Ilina, N; Latysheva, E; Latysheva, T; Nazarova, E, 2021) |
| " Safety determination was assessed by evaluating local and systemic adverse events." | 1.62 | Evaluation of safety and tolerability of a rush up-dosing allergen-specific immunotherapy with grass pollen, birch, hazel, and alder allergoid in children with allergic rhinoconjunctivitis, with or without asthma. ( Barberi, S; Ciprandi, G; Licari, A; Marseglia, GL; Martelli, A; Tosca, MA; Traina, G, 2021) |
| "The rate of pollinosis complication in the OAS group was 67." | 1.56 | Epidemiological study of oral allergy syndrome in birch pollen dispersal-free regions. ( Fujieda, S; Ito, Y; Kanno, M; Kato, Y; Kohno, Y; Mori, S; Morikawa, T; Okamoto, M; Osawa, Y; Sugimoto, C; Takabayashi, T; Takahashi, N, 2020) |
| "Patients (n = 52) with birch pollen allergy and prFA to apples were subjected to a prick-to-prick test (SPT) with 23 cultivars (red-fleshed, old traditional and new commercial)." | 1.56 | Allergen-specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy. ( Ahammer, L; Cova, V; Covaciu, CE; Eidelpes, R; Eisendle, K; Letschka, T; Nothegger, B; Platzgummer, S; Reider, N; Tollinger, M; Unterhauser, J, 2020) |
| "Birch pollen allergy is among the most prevalent pollen allergies in Northern and Central Europe." | 1.56 | Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG ( Bax, HJ; Bianchini, R; Crescioli, S; Fazekas-Singer, J; Flicker, S; Hofer, G; Hufnagl, K; Jensen-Jarolim, E; Karagiannis, SN; Keller, W; Köhler, VK; Pranger, CL, 2020) |
| " Relatively minor, immunostimulatory effects were seen following repeated subcutaneous dosing (once every 2 weeks for 13 weeks) as reversible increased white cell count (notably neutrophils), increased globulin level (resulting in decreased albumin/globulin [A/G] ratio) and increased fibrinogen, as well as minor dose site reaction in the form of inflammatory cell infiltrate." | 1.51 | Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development. ( Baldrick, P; Heath, MD; Hutchings, JW; Skinner, MA, 2019) |
| "Birch pollen allergy is a common cause of spring pollinosis in China." | 1.51 | Chinese Birch Pollen Allergy and Immunotherapy in Mice. ( Xie, Z; Yin, J, 2019) |
| "Pollinosis is sub-diagnosed and rarely studied in tropical countries." | 1.51 | Cashew Tree Pollen: An Unknown Source of IgE-Reactive Molecules. ( Briza, P; Bussador do Amaral, J; Danella Figo, D; De Amicis, K; de Oliveira Martins, C; Eduardo Santos Galvão, C; Fernandes Morato Castro, F; Gadermaier, G; Kalil, J; Neiva Santos de Aquino, D; Pomiecinski, F; Souza Santos, K, 2019) |
| "In patients with AD and birch pollen allergy, birch pollen-related foods should be considered as a provocation factor for an aggravation of disease signs and symptoms." | 1.48 | Birch pollen-related foods can cause late eczematous reactions in patients with atopic dermatitis. ( Heratizadeh, A; Wassmann-Otto, A; Werfel, T; Wichmann, K, 2018) |
| "Birch allergy (BA) is a common pollinosis caused by the allergens Bet v 1, Bet v 2, and Bet v 4." | 1.43 | Profiles of Birch Sensitization (Bet v 1, Bet v 2, and Bet v 4) and Oral Allergy Syndrome Across Italy. ( Barocci, F; Ciprandi, G; Comite, P; De Amici, M; Marseglia, GL; Mussap, M; Quaglini, S; Scala, E, 2016) |
| "Patients with birch pollen allergy with AD had higher Bet v 1-specific proliferation of CLA(+) and CCR4(+) T cells compared with patients with birch pollen allergy without AD." | 1.43 | Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. ( Blatt, K; Brodie, TM; Campana, R; Henning, R; Hoermann, G; Huber, H; Kaider, A; Marth, K; Moritz, K; Neubauer, A; Sallusto, F; Valent, P; Valenta, R; Wöhrl, S, 2016) |
| "Among the 167 patients with birch-pollen allergy and GAS on ingestion of any of the foods, there were 16 cases (10%) with OAS following soy milk ingestion." | 1.42 | [Oral Allergy Syndrome Following Soy Milk Ingestion in Patients with Birch Pollen Allergy]. ( Asakura, K; Himi, T; Shirasaki, H; Yamamoto, T, 2015) |
| "Birch pollen allergy represents the main cause of winter and spring pollinosis in the temperate climate zone of the northern hemisphere and sensitization towards Bet v 1, the major birch pollen allergen, affects over 100 million allergic patients." | 1.40 | Bet v 1--a Trojan horse for small ligands boosting allergic sensitization? ( Aglas, L; Almeida, FC; Asam, C; Batista, AL; Bohle, B; de Paula, VS; Ebner, C; Ferreira, F; Kitzmüller, C; Moraes, AH; Valente, AP; Wallner, M, 2014) |
| "Parental hay fever and specific IgE to grass and/or birch pollen are strong pre-clinical determinants and potentially good predictors of seasonal allergic rhinitis." | 1.40 | Parental hay fever reinforces IgE to pollen as pre-clinical biomarker of hay fever in childhood. ( Bauer, CP; Forster, J; Hakimeh, D; Hatzler, L; Hoffman, U; Hofmaier, S; Illi, S; Keil, T; Lau, S; Matricardi, PM; Panetta, V; Rohrbach, A; Schuster, A; Stock, P; Wahn, U; Zepp, F, 2014) |
| "The symptoms of pollen allergy in the European population occur in a period of increased pollen precipitation, and take the form of allergic rhinitis and conjunctivitis, bronchial asthma, contact urticaria, and food allergy." | 1.39 | [Oral allergy syndrome in patients with pollen allergy]. ( Chimielewska, A; Czarnobilska, E; Dyga, W; Mazur, M; Myszkowska, D; Obtułowicz, K; Sacha, M, 2013) |
| "Asthmatics reporting hay fever but who were not sensitised to grass showed no seasonal variations." | 1.39 | The influence of sensitisation to pollens and moulds on seasonal variations in asthma attacks. ( Abramson, M; Anto, JM; Burney, P; Burr, M; Canova, C; Cerveri, I; Crane, J; de Marco, R; Gislason, T; Heinrich, J; Janson, C; Jarvis, D; Kuenzli, N; Leynaert, B; Manfreda, J; Nowak, D; Pin, I; Smith, M; Svanes, C; Toren, K; Wjst, M; Zock, JP, 2013) |
| "Of 15 subjects with birch pollen allergy and being suspected of soy allergy, eight of them proved to be SA; 7/15 subjects proved to be soy tolerant (ST)." | 1.38 | Secondary soy allergy in children with birch pollen allergy may cause both chronic and acute symptoms. ( De Swert, LF; Gadisseur, R; Leus, J; Raes, M; Sjölander, S; Van Hoeyveld, E, 2012) |
| "Patients with birch pollen allergy may suffer from severe anaphylactic reactions after ingestion of foodstuffs containing soya." | 1.38 | [Anaphylactic reaction after soya intake in a patient with birch pollen allergy]. ( El-Hifnawi, D; Hardt, A; Hauswald, B; Neudert, M; Zahnert, T, 2012) |
| "Birch pollen is the major allergen in pollinosis in northern Japan." | 1.35 | Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4. ( Himi, T; Koyanagi, Y; Shirasaki, H; Watanabe, N; Yamamoto, T, 2008) |
| "Fexofenadine is a second-generation histamine receptor blocker well known for its potent interaction with this inflammatory process." | 1.35 | Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis. ( Ewert, R; Gläser, S; Gustavus, B; Hanf, G; Koch, B; Kunkel, G; Noga, O; Schäper, C, 2009) |
| "Pollen allergy is characterized by seasonal allergic manifestations affecting patients during the plant pollen season." | 1.34 | Incidence of Betulaceae pollen and pollinosis in Zagreb, Croatia, 2002-2005. ( Culig, J; Hrga, I; Milanović, SM; Mileta, T; Peternel, R, 2007) |
| "An episode of treated allergic rhinitis, rhinosinusitus, or conjunctivitis (ARC) was defined as the association of an oral antihistamine and a local antiallergic drug on the same prescription." | 1.34 | Short-term effect of pollen exposure on antiallergic drug consumption. ( Caillaud, D; Delmas, MC; Fuhrman, C; Lecadet, J; Sarter, H; Thibaudon, M; Zeghnoun, A, 2007) |
| "Thirty schoolchildren with birch pollen allergy and 30 healthy controls from the same schools were included in the study." | 1.33 | Low levels of CC16 in nasal fluid of children with birch pollen-induced rhinitis. ( Benson, M; Johansson, S; Keen, C; Ståhl, A; Wennergren, G, 2005) |
| "In conclusion grass pollinosis is frequently associated with polysensitization to other pollen and food allergens." | 1.33 | Relationship between Bet v 1 and Bet v 2 specific IgE and food allergy in children with grass pollen respiratory allergy. ( Bellini, F; Masi, M; Menna, G; Miniaci, A; Ricci, G; Righetti, F, 2005) |
| "Sneezing was more common in SNAR and SAR than in PNAR; eye-symptoms more prominent in SAR than in SNAR or PNAR." | 1.33 | Seasonal non-allergic rhinitis (SNAR)--a new disease entity? A clinical and immunological comparison between SNAR, seasonal allergic rhinitis and persistent non-allergic rhinitis. ( Enbom, H; Eriksson, NE; Malcus, I; Movérare, R; Wedbäck, A, 2005) |
| "Patients with birch pollen allergy should avoid the intake of soy protein." | 1.33 | [Anaphylactic reaction to soy drink in three patients with birch pollen allergy]. ( Rytter, M; Simon, JC; Sticherling, M; Süss, A, 2005) |
| "It is unknown whether this food allergy is caused by direct sensitization or cross-sensitization to pollen allergens." | 1.32 | Allergy to jackfruit: a novel example of Bet v 1-related food allergy. ( Bolhaar, ST; Bruijnzeel-Koomen, CA; Knulst, AC; Ree, R; Zuidmeer, L, 2004) |
| "Symptoms of pollen allergy in springtime in Middle and Northern Europe are mainly caused by pollen grains of birch, hazel and alder." | 1.32 | Comparison of Alnus, Corylus and Betula pollen counts in Lublin (Poland) and Skien (Norway). ( Piotrowska, K, 2004) |
| "Pollen-related food allergy to fresh fruits and vegetables is a well-known clinical phenomenon." | 1.32 | Diagnostic value of birch recombinant allergens (rBet v 1, profilin rBet v 2) in children with pollen-related food allergy. ( Cudowska, B; Kaczmarski, M, 2004) |
| "Birch pollen allergy (16/20) was common, along with oral allergy syndrome to apple (12/20) or hazelnut (11/20)." | 1.31 | Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1- related PR-10 protein in soybean, SAM22. ( Crowell, DN; Haustein, UF; Kleine-Tebbe, J; Vieths, S; Vogel, L, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.36) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 103 (36.65) | 29.6817 |
| 2010's | 148 (52.67) | 24.3611 |
| 2020's | 29 (10.32) | 2.80 |
| Authors | Studies |
|---|---|
| Carlsen, HK | 1 |
| Haga, SL | 1 |
| Olsson, D | 1 |
| Behndig, AF | 1 |
| Modig, L | 1 |
| Meister, K | 1 |
| Forsberg, B | 1 |
| Olin, AC | 2 |
| Bahbah, F | 1 |
| Gentil, C | 1 |
| Sousa-Pinto, B | 1 |
| Canonica, GW | 4 |
| Devillier, P | 1 |
| Pfaar, O | 6 |
| Bousquet, J | 1 |
| Wagner, W | 2 |
| Buczyłko, K | 3 |
| Wagner, A | 4 |
| Szwed-Kowalska, A | 1 |
| Stasiak, A | 1 |
| Ahlbeck, L | 1 |
| Ahlberg, E | 1 |
| Stuivers, L | 1 |
| Björkander, J | 3 |
| Nyström, U | 1 |
| Retsas, P | 1 |
| Govindaraj, D | 1 |
| Jenmalm, MC | 1 |
| Duchén, K | 1 |
| Briceno Noriega, D | 1 |
| Savelkoul, HFJ | 1 |
| Jansen, A | 1 |
| Teodorowicz, M | 1 |
| Ruinemans-Koerts, J | 2 |
| Hjalmarsson, E | 2 |
| Hellkvist, L | 2 |
| Karlsson, A | 2 |
| Winquist, O | 1 |
| Kumlien Georén, S | 2 |
| Westin, U | 2 |
| Cardell, LO | 11 |
| Baldrick, P | 1 |
| Hutchings, JW | 1 |
| Heath, MD | 1 |
| Skinner, MA | 1 |
| Ose, R | 2 |
| Tu, J | 1 |
| Schink, A | 1 |
| Maxeiner, J | 1 |
| Schuster, P | 1 |
| Lucas, K | 1 |
| Saloga, J | 3 |
| Bellinghausen, I | 3 |
| Osawa, Y | 1 |
| Ito, Y | 2 |
| Takahashi, N | 1 |
| Sugimoto, C | 1 |
| Kohno, Y | 1 |
| Mori, S | 1 |
| Morikawa, T | 1 |
| Kato, Y | 1 |
| Okamoto, M | 1 |
| Kanno, M | 1 |
| Takabayashi, T | 1 |
| Fujieda, S | 1 |
| Nothegger, B | 1 |
| Reider, N | 1 |
| Covaciu, CE | 1 |
| Cova, V | 1 |
| Ahammer, L | 1 |
| Eidelpes, R | 1 |
| Unterhauser, J | 1 |
| Platzgummer, S | 1 |
| Tollinger, M | 1 |
| Letschka, T | 1 |
| Eisendle, K | 1 |
| Blome, C | 1 |
| Hadler, M | 1 |
| Karagiannis, E | 1 |
| Kisch, J | 1 |
| Neht, C | 1 |
| Kressel, N | 1 |
| Augustin, M | 1 |
| Bergmann, KC | 4 |
| Buters, J | 1 |
| Karatzas, K | 1 |
| Tasioulis, T | 1 |
| Werchan, B | 2 |
| Werchan, M | 2 |
| Köhler, VK | 1 |
| Crescioli, S | 1 |
| Fazekas-Singer, J | 1 |
| Bax, HJ | 1 |
| Hofer, G | 1 |
| Pranger, CL | 1 |
| Hufnagl, K | 4 |
| Bianchini, R | 1 |
| Flicker, S | 1 |
| Keller, W | 4 |
| Karagiannis, SN | 1 |
| Jensen-Jarolim, E | 1 |
| Mikus, M | 1 |
| Zandian, A | 1 |
| Sjöberg, R | 1 |
| Hamsten, C | 1 |
| Forsström, B | 1 |
| Andersson, M | 8 |
| Greiff, L | 6 |
| Uhlén, M | 1 |
| Levin, M | 1 |
| Nilsson, P | 1 |
| van Hage, M | 6 |
| Ohlin, M | 1 |
| Ramírez Caballero, L | 1 |
| Kny, C | 1 |
| Treudler, R | 3 |
| Simon, JC | 4 |
| Kern, K | 1 |
| Jappe, U | 2 |
| Szardenings, M | 1 |
| de Weger, LA | 1 |
| Molster, F | 1 |
| de Raat, K | 1 |
| den Haan, J | 1 |
| Romein, J | 1 |
| van Leeuwen, W | 1 |
| de Groot, H | 2 |
| Mostert, M | 1 |
| Hiemstra, PS | 2 |
| Eljaszewicz, A | 1 |
| Ruchti, F | 1 |
| Radzikowska, U | 1 |
| Globinska, A | 1 |
| Boonpiyathad, T | 1 |
| Gschwend, A | 1 |
| Morita, H | 1 |
| Helbling, A | 2 |
| Arasi, S | 1 |
| Kahlert, H | 2 |
| Berek, N | 1 |
| Nandy, A | 2 |
| Akdis, M | 1 |
| Willers, C | 1 |
| Moniuszko, M | 1 |
| Akdis, CA | 1 |
| Sokolowska, M | 1 |
| Cecchi, L | 1 |
| Scala, E | 2 |
| Caronni, S | 1 |
| Citterio, S | 1 |
| Asero, R | 3 |
| Würtzen, PA | 6 |
| Grønager, PM | 1 |
| Lund, G | 3 |
| Gupta, S | 1 |
| Andersen, PS | 1 |
| Biedermann, T | 7 |
| Ipsen, H | 5 |
| Airouche, S | 3 |
| Beltrami, V | 1 |
| Fleury, S | 1 |
| Batard, T | 1 |
| Bordas-Le Floch, V | 2 |
| Stegmann, T | 1 |
| Amacker, M | 1 |
| Kettner, A | 1 |
| Mascarell, L | 4 |
| Ballardini, N | 1 |
| Bergström, A | 1 |
| Kull, I | 1 |
| Almqvist, C | 1 |
| Andersson, N | 1 |
| Asarnoj, A | 3 |
| Borres, MP | 2 |
| Georgellis, A | 1 |
| Pershagen, G | 2 |
| Westman, M | 1 |
| Melén, E | 1 |
| Huber, S | 1 |
| Lang, R | 1 |
| Asam, C | 3 |
| Ferreira, F | 4 |
| Hawranek, T | 1 |
| Gadermaier, G | 2 |
| Traina, G | 1 |
| Martelli, A | 1 |
| Barberi, S | 2 |
| Licari, A | 1 |
| Marseglia, GL | 3 |
| Tosca, MA | 2 |
| Ciprandi, G | 10 |
| Weigmann, B | 1 |
| Schuppan, D | 1 |
| Waisman, A | 1 |
| Gevaert, P | 1 |
| De Craemer, J | 1 |
| De Ruyck, N | 1 |
| Rottey, S | 1 |
| de Hoon, J | 1 |
| Hellings, PW | 1 |
| Volckaert, B | 1 |
| Lesneuck, K | 1 |
| Orengo, JM | 1 |
| Atanasio, A | 1 |
| Kamal, MA | 1 |
| Abdallah, H | 1 |
| Kamat, V | 1 |
| Dingman, R | 1 |
| DeVeaux, M | 2 |
| Ramesh, D | 2 |
| Perlee, L | 1 |
| Wang, CQ | 2 |
| Weinreich, DM | 1 |
| Herman, G | 1 |
| Yancopoulos, GD | 1 |
| O'Brien, MP | 2 |
| Erhard, SM | 1 |
| Bellach, J | 1 |
| Yürek, S | 1 |
| Tschirner, S | 1 |
| Trendelenburg, V | 1 |
| Grabenhenrich, LB | 1 |
| Fernandez-Rivas, M | 1 |
| van Ree, R | 6 |
| Keil, T | 2 |
| Beyer, K | 1 |
| Ellis, AK | 2 |
| Steacy, L | 1 |
| Suprun, M | 1 |
| Langdon, S | 1 |
| Adams, D | 1 |
| Thiele, J | 1 |
| Walker, T | 1 |
| Perlee, LT | 1 |
| Latysheva, E | 1 |
| Nazarova, E | 1 |
| Latysheva, T | 1 |
| Ilina, N | 1 |
| Kubik-Komar, A | 1 |
| Piotrowska-Weryszko, K | 1 |
| Kuna-Broniowska, I | 1 |
| Weryszko-Chmielewska, E | 1 |
| Kaszewski, BM | 1 |
| Mücke, HG | 1 |
| Gauger, U | 1 |
| Simoleit, A | 1 |
| Zuberbier, T | 4 |
| van der Werf, JF | 1 |
| Boot, D | 1 |
| Gellrich, D | 1 |
| Eder, K | 1 |
| San Nicoló, M | 1 |
| Berghaus, A | 1 |
| Gröger, M | 1 |
| Shalaby, KH | 1 |
| Al Heialy, S | 1 |
| Tsuchiya, K | 1 |
| Farahnak, S | 1 |
| McGovern, TK | 1 |
| Risse, PA | 1 |
| Suh, WK | 1 |
| Qureshi, ST | 1 |
| Martin, JG | 1 |
| Schülke, S | 1 |
| Fiedler, AH | 1 |
| Junker, AC | 1 |
| Flaczyk, A | 1 |
| Wolfheimer, S | 1 |
| Wangorsch, A | 1 |
| Heinz, A | 1 |
| Beckert, H | 1 |
| Nagl, B | 3 |
| Bohle, B | 11 |
| Vieths, S | 6 |
| Toda, M | 1 |
| Scheurer, S | 1 |
| Incorvaia, C | 2 |
| Ridolo, E | 2 |
| Mauro, M | 2 |
| Russello, M | 2 |
| Pastorello, E | 2 |
| Muluk, NB | 1 |
| Cingi, C | 1 |
| Tenn, MW | 1 |
| Steacy, LM | 1 |
| Adams, DE | 1 |
| Day, AG | 1 |
| Walker, TJ | 1 |
| Nolte, H | 1 |
| Wassmann-Otto, A | 1 |
| Heratizadeh, A | 1 |
| Wichmann, K | 1 |
| Werfel, T | 3 |
| Worm, M | 6 |
| Higenbottam, T | 1 |
| Mösges, R | 1 |
| Aberer, W | 1 |
| Gunawardena, K | 1 |
| Wessiepe, D | 1 |
| Lee, D | 1 |
| Kramer, MF | 1 |
| Skinner, M | 1 |
| Lees, B | 1 |
| Zielen, S | 6 |
| Lundkvist, K | 1 |
| Winqvist, O | 1 |
| Polak, D | 2 |
| Hafner, C | 2 |
| Briza, P | 4 |
| Kitzmüller, C | 2 |
| Elbe-Bürger, A | 1 |
| Samadi, N | 2 |
| Gschwandtner, M | 1 |
| Pfützner, W | 4 |
| Zlabinger, GJ | 1 |
| Jahn-Schmid, B | 3 |
| Kurze, E | 1 |
| Kock, V | 1 |
| Lo Scalzo, R | 1 |
| Olbricht, K | 1 |
| Schwab, W | 1 |
| Zhu, C | 1 |
| Farah, J | 1 |
| Choël, M | 1 |
| Gosselin, S | 1 |
| Baroudi, M | 1 |
| Petitprez, D | 1 |
| Visez, N | 1 |
| Olcese, R | 1 |
| Silvestri, M | 1 |
| Del Barba, P | 1 |
| Brolatti, N | 1 |
| van Rijt, LS | 1 |
| Logiantara, A | 1 |
| Canbaz, D | 1 |
| Couroux, P | 1 |
| Stage, BS | 2 |
| Damkjaer, JT | 1 |
| Steffensen, MA | 1 |
| Salapatek, AM | 1 |
| Lund, K | 2 |
| Campana, R | 4 |
| Marth, K | 4 |
| Zieglmayer, P | 1 |
| Weber, M | 1 |
| Lupinek, C | 2 |
| Zhernov, Y | 1 |
| Elisyutina, O | 1 |
| Khaitov, M | 1 |
| Rigler, E | 1 |
| Westritschnig, K | 2 |
| Berger, U | 2 |
| Wolkersdorfer, M | 2 |
| Horak, F | 6 |
| Valenta, R | 16 |
| Bachert, C | 1 |
| Kuna, P | 3 |
| Panzner, P | 4 |
| Džupinová, M | 1 |
| Klimek, L | 5 |
| van Nimwegen, MJ | 1 |
| Boot, JD | 2 |
| Yu, D | 1 |
| Opstelten, DJE | 1 |
| de Kam, PJ | 1 |
| Rak, S | 11 |
| Samoliński, B | 2 |
| Antila, J | 1 |
| Höiby, AS | 2 |
| Kruse, B | 1 |
| Lipiec, A | 1 |
| Rudert, M | 1 |
| Valovirta, E | 9 |
| Vizzardelli, C | 1 |
| Sánchez Acosta, G | 1 |
| Rosskopf, S | 1 |
| Steinberger, P | 1 |
| de Blay, F | 2 |
| Thrane, D | 1 |
| Jacobsen, SH | 1 |
| Winther, L | 2 |
| Seutter von Loetzen, C | 1 |
| Reuter, A | 1 |
| Spiric, J | 1 |
| Schulenborg, T | 1 |
| Völker, E | 1 |
| Vogel, L | 3 |
| Rösch, P | 1 |
| Schiller, D | 1 |
| Xie, Z | 1 |
| Yin, J | 2 |
| Plückhahn, K | 1 |
| Akboga, Y | 1 |
| Rieker-Schwienbacher, J | 1 |
| Thieme, U | 1 |
| Rosewich, M | 2 |
| Hanif, T | 1 |
| Dhaygude, K | 1 |
| Kankainen, M | 1 |
| Renkonen, J | 4 |
| Mattila, P | 4 |
| Ojala, T | 1 |
| Joenväärä, S | 4 |
| Mäkelä, M | 1 |
| Pelkonen, A | 1 |
| Kauppi, P | 1 |
| Haahtela, T | 5 |
| Renkonen, R | 4 |
| Toppila-Salmi, S | 4 |
| Till, SJ | 2 |
| Knulst, A | 1 |
| Rauber, MM | 1 |
| Wu, HK | 1 |
| Adams, B | 1 |
| Pickert, J | 1 |
| Shamji, MH | 2 |
| Möbs, C | 3 |
| Danella Figo, D | 1 |
| De Amicis, K | 1 |
| Neiva Santos de Aquino, D | 1 |
| Pomiecinski, F | 1 |
| Eduardo Santos Galvão, C | 1 |
| Bussador do Amaral, J | 1 |
| de Oliveira Martins, C | 1 |
| Fernandes Morato Castro, F | 1 |
| Kalil, J | 1 |
| Souza Santos, K | 1 |
| Zhang, H | 2 |
| Benson, M | 10 |
| Wang, H | 1 |
| Brinkhaus, B | 1 |
| Ortiz, M | 1 |
| Witt, CM | 1 |
| Roll, S | 1 |
| Linde, K | 1 |
| Pfab, F | 1 |
| Niggemann, B | 4 |
| Hummelsberger, J | 1 |
| Treszl, A | 1 |
| Ring, J | 2 |
| Wegscheider, K | 1 |
| Willich, SN | 1 |
| Breyer, I | 1 |
| Focke-Tejkl, M | 4 |
| Blatt, K | 3 |
| Layhadi, J | 1 |
| Gieras, A | 2 |
| Swoboda, I | 3 |
| Zafred, D | 2 |
| Valent, P | 5 |
| Durham, SR | 2 |
| Canova, C | 1 |
| Heinrich, J | 1 |
| Anto, JM | 1 |
| Leynaert, B | 1 |
| Smith, M | 4 |
| Kuenzli, N | 1 |
| Zock, JP | 1 |
| Janson, C | 1 |
| Cerveri, I | 1 |
| de Marco, R | 1 |
| Toren, K | 1 |
| Gislason, T | 1 |
| Nowak, D | 1 |
| Pin, I | 1 |
| Wjst, M | 1 |
| Manfreda, J | 1 |
| Svanes, C | 1 |
| Crane, J | 1 |
| Abramson, M | 1 |
| Burr, M | 1 |
| Burney, P | 1 |
| Jarvis, D | 1 |
| Smith, KA | 1 |
| Gray, NJ | 1 |
| Cheek, E | 1 |
| Saleh, F | 1 |
| Lavender, J | 1 |
| Frew, AJ | 1 |
| Kern, F | 1 |
| Tarzi, MD | 1 |
| Tourdot, S | 1 |
| Berjont, N | 1 |
| Moussu, H | 1 |
| Betbeder, D | 1 |
| Nony, E | 2 |
| Baron-Bodo, V | 3 |
| Moingeon, P | 4 |
| Ma, S | 1 |
| Jiang, N | 1 |
| Sager, A | 3 |
| Robinson, DS | 2 |
| Meulenbroek, LA | 1 |
| de Jong, RJ | 1 |
| den Hartog Jager, CF | 1 |
| Monsuur, HN | 1 |
| Wouters, D | 1 |
| Nauta, AJ | 1 |
| Knippels, LM | 1 |
| van Neerven, RJ | 3 |
| Ruiter, B | 1 |
| Leusen, JH | 1 |
| Hack, CE | 1 |
| Bruijnzeel-Koomen, CA | 3 |
| Knulst, AC | 3 |
| Garssen, J | 1 |
| van Hoffen, E | 2 |
| Selb, R | 2 |
| Eckl-Dorna, J | 1 |
| Vrtala, S | 8 |
| Niederberger, V | 5 |
| Caillaud, D | 2 |
| Martin, S | 1 |
| Segala, C | 1 |
| Besancenot, JP | 1 |
| Clot, B | 1 |
| Thibaudon, M | 3 |
| Kulis, M | 1 |
| Linhart, B | 1 |
| Narayanan, M | 1 |
| Wrba, F | 1 |
| Lavaud, F | 1 |
| Fore, M | 1 |
| Fontaine, JF | 1 |
| Pérotin, JM | 1 |
| Chimielewska, A | 1 |
| Mazur, M | 1 |
| Sacha, M | 1 |
| Myszkowska, D | 4 |
| Dyga, W | 2 |
| Obtułowicz, K | 1 |
| Czarnobilska, E | 2 |
| Stobiecki, M | 1 |
| Majewska, R | 2 |
| Allam, JP | 1 |
| Wuestenberg, E | 1 |
| Wolf, H | 1 |
| Decot, E | 1 |
| Horn, A | 1 |
| Schnitker, J | 1 |
| Bieber, T | 2 |
| Novak, N | 2 |
| Hatzler, L | 1 |
| Panetta, V | 1 |
| Illi, S | 1 |
| Hofmaier, S | 1 |
| Rohrbach, A | 1 |
| Hakimeh, D | 1 |
| Bauer, CP | 1 |
| Hoffman, U | 1 |
| Forster, J | 1 |
| Zepp, F | 1 |
| Schuster, A | 1 |
| Stock, P | 1 |
| Wahn, U | 6 |
| Lau, S | 1 |
| Matricardi, PM | 1 |
| Shirasaki, H | 6 |
| Yamamoto, T | 6 |
| Saikawa, E | 1 |
| Seki, N | 1 |
| Asakura, K | 4 |
| Kataura, A | 1 |
| Himi, T | 6 |
| Batista, AL | 1 |
| Moraes, AH | 1 |
| de Paula, VS | 1 |
| Almeida, FC | 1 |
| Aglas, L | 1 |
| Ebner, C | 3 |
| Wallner, M | 3 |
| Valente, AP | 1 |
| Cuinica, LG | 1 |
| Cruz, A | 1 |
| Abreu, I | 1 |
| da Silva, JC | 1 |
| Darbinjan, A | 1 |
| Knetschke, T | 1 |
| Neudert, M | 2 |
| Zahnert, T | 2 |
| Hauswald, B | 2 |
| Brandelius, A | 1 |
| Uller, L | 2 |
| Melac, M | 2 |
| Soulie, S | 1 |
| Lescaille, G | 1 |
| Lemoine, F | 1 |
| Jospin, F | 1 |
| Paul, S | 1 |
| Caplier, L | 1 |
| Hasséus, B | 2 |
| Björhn, C | 1 |
| Zeldin, RK | 1 |
| Ackerbauer, D | 1 |
| Bublin, M | 3 |
| Radauer, C | 2 |
| Varga, EM | 1 |
| Szépfalusi, Z | 2 |
| Fröschl, R | 1 |
| Hoffmann-Sommergruber, K | 3 |
| Eiwegger, T | 2 |
| Breiteneder, H | 3 |
| Wollmann, E | 1 |
| Kundi, M | 3 |
| Bastl, K | 1 |
| Kmenta, M | 1 |
| Geller-Bernstein, C | 1 |
| Jäger, S | 2 |
| Ohlsson, AC | 1 |
| Drevsäter, A | 1 |
| Brynnel, M | 1 |
| Johansson, I | 1 |
| Van Hoeyveld, E | 2 |
| Nickmans, S | 1 |
| Ceuppens, JL | 2 |
| Bossuyt, X | 1 |
| Comite, P | 2 |
| Ferrero, F | 1 |
| Minale, P | 1 |
| Voltolini, S | 1 |
| Bignardi, D | 1 |
| Fontana, V | 1 |
| Bruzzone, M | 1 |
| Troise, C | 1 |
| Mussap, M | 2 |
| Spina, L | 1 |
| Weisskopf, M | 1 |
| von Moos, S | 1 |
| Graf, N | 1 |
| Kündig, TM | 1 |
| Senti, G | 1 |
| Ahlström-Emanuelsson, C | 1 |
| Alenäs, M | 1 |
| Almqvist, G | 1 |
| Cervin, A | 1 |
| Dolata, J | 1 |
| Lindgren, S | 1 |
| Mårtensson, A | 1 |
| Young, B | 1 |
| Widegren, H | 1 |
| van Twuijver, E | 1 |
| Opstelten, DJ | 1 |
| Diamant, Z | 1 |
| Kinaciyan, T | 2 |
| Faustmann, S | 1 |
| Kopp, S | 1 |
| Moritz, K | 1 |
| Neubauer, A | 2 |
| Huber, H | 2 |
| Henning, R | 1 |
| Hoermann, G | 1 |
| Brodie, TM | 1 |
| Kaider, A | 1 |
| Sallusto, F | 1 |
| Wöhrl, S | 1 |
| Heneberg, P | 1 |
| Riegerová, K | 1 |
| Kučera, P | 1 |
| Larsson, P | 1 |
| Lärstad, M | 1 |
| Bake, B | 1 |
| Hammar, O | 1 |
| Bredberg, A | 1 |
| Almstrand, AC | 1 |
| Mirgorodskaya, E | 1 |
| Otte, M | 1 |
| Mahler, V | 1 |
| Kerpes, A | 1 |
| Pabst, O | 1 |
| Voehringer, D | 1 |
| Gilles-Stein, S | 1 |
| Beck, I | 1 |
| Chaker, A | 1 |
| Bas, M | 1 |
| McIntyre, M | 1 |
| Cifuentes, L | 1 |
| Petersen, A | 2 |
| Gutermuth, J | 1 |
| Schmidt-Weber, C | 1 |
| Behrendt, H | 3 |
| Traidl-Hoffmann, C | 2 |
| Floch, VB | 1 |
| Hao, GD | 1 |
| Zheng, YW | 1 |
| Wang, ZX | 1 |
| Kong, XA | 1 |
| Song, ZJ | 1 |
| Lai, XX | 1 |
| Spangfort, MD | 1 |
| Schabussova, I | 3 |
| Drinic, M | 1 |
| Akgün, J | 1 |
| Loupal, G | 2 |
| Joachim, A | 1 |
| Wiedermann, U | 4 |
| De Amici, M | 4 |
| Quaglini, S | 2 |
| Barocci, F | 1 |
| Wölbing, F | 1 |
| Kunz, J | 1 |
| Kempf, WE | 1 |
| Grimmel, C | 1 |
| Fischer, J | 1 |
| Malkiewicz, M | 1 |
| Drzeniecka-Osiadacz, A | 1 |
| Krynicka, J | 1 |
| Szwed, A | 1 |
| Killingbeck, SS | 1 |
| Ge, MQ | 1 |
| Haczku, A | 1 |
| Abe, S | 1 |
| Kanaizumi, E | 1 |
| Kikuchi, M | 1 |
| Franke, A | 1 |
| Schmiedeknecht, A | 1 |
| Ballmer-Weber, B | 1 |
| Schmitt, J | 1 |
| Brehler, R | 1 |
| Kleinheinz, A | 1 |
| Kleine-Tebbe, J | 2 |
| Brüning, H | 1 |
| Ruëff, F | 1 |
| Schäkel, K | 1 |
| Holzhauser, T | 1 |
| Mattson, L | 1 |
| Lentini, A | 1 |
| Gawel, DR | 1 |
| Badam, TV | 1 |
| Ledin, T | 1 |
| Nestor, CE | 1 |
| Gustafsson, M | 1 |
| Serra-Musach, J | 1 |
| Xiang, Z | 1 |
| Ernst, D | 1 |
| Kraller, M | 1 |
| Babina, M | 1 |
| Blockhuys, M | 1 |
| Faber, MA | 1 |
| Sabato, V | 3 |
| Hubens, G | 1 |
| Ebo, DG | 5 |
| Arvidsson, M | 4 |
| Fenoglio, D | 3 |
| Negrini, S | 2 |
| Filaci, G | 2 |
| Swiebocka, E | 1 |
| Siergiejko, Z | 1 |
| Siergiejko, G | 1 |
| Leoniuk, A | 1 |
| Hofman, J | 1 |
| Aerts, NE | 1 |
| Dombrecht, EJ | 1 |
| Bridts, CH | 4 |
| Hagendorens, MM | 2 |
| de Clerck, LS | 4 |
| Stevens, WJ | 2 |
| Pauli, G | 5 |
| Larsen, TH | 1 |
| Purohit, A | 3 |
| Kavina, A | 1 |
| Schroeder, JW | 1 |
| Mothes, N | 1 |
| Spitzauer, S | 4 |
| Montagut, A | 1 |
| Galvain, S | 1 |
| André, C | 2 |
| Poulsen, LK | 6 |
| Malling, HJ | 5 |
| Skjøth, CA | 2 |
| Brandt, J | 2 |
| Emberlin, J | 3 |
| Werner, M | 1 |
| Thiery, J | 1 |
| Kramer, S | 1 |
| Gebhardt, C | 1 |
| Averbeck, M | 1 |
| Suess, A | 1 |
| Murdaca, G | 2 |
| Ricciardolo, F | 1 |
| Marseglia, G | 1 |
| Tosca, M | 2 |
| Boehm, I | 1 |
| Brenac Brochier, V | 1 |
| Chabre, H | 1 |
| Lautrette, A | 1 |
| Ravault, V | 1 |
| Couret, MN | 1 |
| Didierlaurent, A | 1 |
| Woschnagg, C | 2 |
| Forsberg, J | 1 |
| Engström, A | 1 |
| Odreman, F | 1 |
| Venge, P | 2 |
| Garcia, RC | 1 |
| Ouwehand, AC | 1 |
| Nermes, M | 1 |
| Collado, MC | 1 |
| Rautonen, N | 1 |
| Salminen, S | 1 |
| Isolauri, E | 1 |
| Bergmann-Hug, K | 1 |
| Wirth, R | 1 |
| Henseler, M | 1 |
| Pichler, WJ | 2 |
| Schnyder, B | 2 |
| Rubin, J | 1 |
| Ostblom, E | 2 |
| Ahlstedt, S | 2 |
| Hedlin, G | 3 |
| Lilja, G | 3 |
| Wickman, M | 2 |
| Parviainen, V | 2 |
| Alff-Tuomala, S | 1 |
| Nicorici, D | 1 |
| Twardosz-Kropfmüller, A | 1 |
| Singh, MB | 1 |
| Kraft, D | 1 |
| Thunberg, S | 2 |
| Gafvelin, G | 3 |
| Nord, M | 1 |
| Grönneberg, R | 2 |
| Grunewald, J | 2 |
| Eklund, A | 2 |
| Baek, CH | 1 |
| Bae, YJ | 1 |
| Cho, YS | 1 |
| Moon, HB | 1 |
| Kim, TB | 1 |
| Battaglia, F | 1 |
| Slotosch, C | 2 |
| Löffler, H | 1 |
| Jakob, T | 1 |
| Hertl, M | 2 |
| Bullens, D | 2 |
| Kleinjans, H | 1 |
| van der Werf, J | 1 |
| Schäper, C | 1 |
| Gustavus, B | 1 |
| Koch, B | 1 |
| Ewert, R | 1 |
| Hanf, G | 1 |
| Kunkel, G | 1 |
| Noga, O | 2 |
| Gläser, S | 1 |
| Röder, A | 1 |
| Darrelmann, N | 1 |
| Klingenberg, W | 1 |
| Krüll, M | 1 |
| Suttorp, N | 1 |
| Buters, JT | 2 |
| Weichenmeier, I | 2 |
| Ochs, S | 1 |
| Pusch, G | 1 |
| Kreyling, W | 1 |
| Boere, AJ | 1 |
| Schober, W | 2 |
| Mutschlechner, S | 2 |
| Egger, M | 1 |
| Lackner, P | 1 |
| Karle, A | 1 |
| Vogt, AB | 1 |
| Fischer, GF | 1 |
| Movérare, R | 4 |
| Poorafshar, M | 1 |
| van Zuuren, EJ | 1 |
| Terreehorst, I | 1 |
| Tupker, RA | 1 |
| Akkerdaas, JH | 1 |
| Larenas-Linnemann, D | 1 |
| Emanuelsson, CA | 1 |
| Erjefält, JS | 3 |
| Persson, CG | 4 |
| Marogna, M | 2 |
| Colombo, F | 1 |
| Spadolini, I | 1 |
| Massolo, A | 2 |
| Berra, D | 2 |
| Zanon, P | 2 |
| Chiodini, E | 2 |
| Passalacqua, G | 3 |
| Lalek, N | 1 |
| Kosnik, M | 1 |
| Silar, M | 1 |
| Korosec, P | 1 |
| Wilson, D | 1 |
| Evans, M | 1 |
| Guthrie, N | 1 |
| Sharma, P | 1 |
| Baisley, J | 1 |
| Schonlau, F | 1 |
| Burki, C | 1 |
| Smole, U | 1 |
| Wagner, S | 1 |
| Balazs, N | 1 |
| Allmaier, G | 1 |
| Novatchkova, M | 1 |
| Jenisch, S | 1 |
| Kabelitz, D | 1 |
| Maderegger, B | 1 |
| Jertschin, P | 1 |
| Stegfellner, G | 1 |
| Strand, V | 1 |
| Egger, C | 1 |
| Narkus, A | 1 |
| Kniest, F | 1 |
| Menzel, A | 2 |
| Meyer, H | 1 |
| Sprung, V | 1 |
| Peeters, KA | 1 |
| van der Tas, CW | 1 |
| Zuidmeer, L | 2 |
| van Ieperen-van Dijk, AG | 1 |
| Knol, EF | 1 |
| Vissers, YM | 2 |
| Snel, J | 2 |
| Zuurendonk, PF | 1 |
| Kleerebezem, M | 2 |
| Wichers, HJ | 1 |
| Savelkoul, HF | 2 |
| Smit, BA | 1 |
| Jongen, JM | 1 |
| van der Meulen, ET | 1 |
| Zwijsen, R | 1 |
| Jansen, AP | 1 |
| Saarinen, K | 1 |
| Jantunen, J | 1 |
| Fohr, M | 1 |
| Baumgartner, C | 1 |
| Wild, C | 1 |
| Nutten, S | 2 |
| Zuercher, AW | 1 |
| Mercenier, A | 2 |
| Fontaine, M | 1 |
| Dubost, J | 1 |
| Bienvenu, F | 1 |
| Ferrenq Dubost, R | 1 |
| Proton, G | 1 |
| Piriou, V | 1 |
| Ekman, AK | 2 |
| Jansson, L | 2 |
| Barnes, CS | 1 |
| Amado, M | 1 |
| Thaci, D | 1 |
| Hoffmann, M | 1 |
| Fölster-Holst, R | 1 |
| Homey, B | 1 |
| Schaekel, K | 1 |
| Stefan, JA | 1 |
| Bodtger, U | 2 |
| Assing, K | 3 |
| Bégin, P | 1 |
| Des Roches, A | 1 |
| Nguyen, M | 1 |
| Masse, MS | 1 |
| Paradis, J | 1 |
| Paradis, L | 1 |
| Hauser, M | 1 |
| Himly, M | 1 |
| Zaborsky, N | 1 |
| Harrer, A | 1 |
| Pichler, U | 1 |
| Thalhamer, J | 2 |
| Achatz, G | 1 |
| Ballmer-Weber, BK | 3 |
| Skypala, IJ | 1 |
| Calderon, MA | 1 |
| Leeds, AR | 1 |
| Emery, P | 1 |
| Åberg, N | 1 |
| Dahl, Å | 1 |
| El-Hifnawi, D | 1 |
| Hardt, A | 1 |
| De Swert, LF | 1 |
| Gadisseur, R | 1 |
| Sjölander, S | 2 |
| Raes, M | 1 |
| Leus, J | 1 |
| Kopac, P | 1 |
| Rudin, M | 1 |
| Gentinetta, T | 1 |
| Gerber, R | 1 |
| Pichler, Ch | 1 |
| Hausmann, O | 1 |
| Cirillo, I | 1 |
| Verweij, MM | 3 |
| Nullens, S | 1 |
| Levi-Schaffer, F | 1 |
| Gibbs, BF | 1 |
| Schiavino, D | 1 |
| Lombardi, C | 1 |
| Fukutomi, Y | 2 |
| Nakazawa, T | 1 |
| Ishii, T | 1 |
| Nakayama, S | 1 |
| Tanaka, A | 1 |
| Taniguchi, M | 2 |
| Saito, A | 1 |
| Yasueda, H | 1 |
| Nakamura, H | 1 |
| Akiyama, K | 2 |
| Villalta, D | 1 |
| Lundström, SL | 1 |
| Yang, J | 1 |
| Källberg, HJ | 1 |
| Haeggström, JZ | 1 |
| Hammock, BD | 1 |
| Wheelock, ÅM | 1 |
| Wheelock, CE | 1 |
| Pałgan, K | 1 |
| Götz-Żbikowska, M | 1 |
| Tykwińska, M | 1 |
| Napiórkowska, K | 1 |
| Bartuzi, Z | 1 |
| Virtala, R | 1 |
| Fransson, M | 2 |
| Adner, M | 2 |
| Tang, ML | 1 |
| Hoflehner, E | 1 |
| Zuercher, A | 1 |
| Trashin, S | 1 |
| Cucu, T | 1 |
| De Meulenaer, B | 1 |
| Devreese, B | 1 |
| Bellanger, AP | 1 |
| Bosch-Cano, F | 1 |
| Millon, L | 1 |
| Ruffaldi, P | 1 |
| Franchi, M | 1 |
| Bernard, N | 1 |
| Geroldinger-Simic, M | 1 |
| Baumgartner-Durchschlag, U | 1 |
| Lidholm, J | 1 |
| Bartel, D | 1 |
| Mayer, L | 1 |
| Campbell, H | 1 |
| Escudier, MP | 1 |
| Brostoff, J | 1 |
| Patel, P | 1 |
| Milligan, P | 1 |
| Challacombe, SJ | 1 |
| Sanderson, JD | 1 |
| Lomer, MC | 1 |
| Puc, M | 1 |
| Hylander, T | 1 |
| Latif, L | 1 |
| Petersson-Westin, U | 1 |
| De Swert, L | 1 |
| Veereman, G | 1 |
| Dilissen, E | 1 |
| Bosmans, E | 1 |
| Mattelaer, C | 1 |
| Yamagiwa, M | 1 |
| Hattori, R | 1 |
| Yamamoto, S | 1 |
| Kanba, M | 1 |
| Tasaki, T | 1 |
| Ueda, K | 1 |
| Nishizumi, T | 1 |
| Svensson, M | 1 |
| Hayek, B | 2 |
| Bende, M | 1 |
| Sorva, R | 1 |
| Elfman, L | 2 |
| Detandt, M | 1 |
| Gehrig, R | 1 |
| Jaeger, S | 1 |
| Nolard, N | 1 |
| Rantio-Lehtimäki, A | 1 |
| Kopp, MV | 2 |
| Brauburger, J | 2 |
| Riedinger, F | 1 |
| Beischer, D | 1 |
| Ihorst, G | 1 |
| Kamin, W | 4 |
| Friedrichs, F | 2 |
| Von Berg, A | 3 |
| Gerhold, K | 1 |
| Hamelmann, E | 2 |
| Kuehr, J | 4 |
| Crowell, DN | 1 |
| Haustein, UF | 1 |
| Meyer, P | 1 |
| Carlsson, B | 1 |
| Carlsson, LM | 1 |
| Wennergren, G | 4 |
| Lachasse, C | 1 |
| Laaidi, M | 2 |
| Laaidi, K | 1 |
| Rigollet, S | 1 |
| Jahnz-Rózyk, K | 1 |
| Targowski, T | 1 |
| Głodzinska-Wyszogrodzka, E | 1 |
| Płusa, T | 1 |
| Tresch, S | 1 |
| Holzmann, D | 1 |
| Baumann, S | 1 |
| Blaser, K | 1 |
| Wüthrich, B | 3 |
| Crameri, R | 1 |
| Schmid-Grendelmeier, P | 1 |
| BROWN, EA | 1 |
| Vermeulen, AM | 1 |
| Groenewoud, GC | 1 |
| de Jong, NW | 1 |
| Gerth van Wijk, R | 1 |
| van Toorenenbergen, AW | 1 |
| Weber, RW | 1 |
| Roever, AC | 1 |
| Heine, G | 1 |
| Khinchi, MS | 1 |
| Carat, F | 1 |
| Hansen, AB | 1 |
| Wosinska-Becler, K | 1 |
| Plewako, H | 2 |
| Håkansson, L | 1 |
| Modrzyński, M | 3 |
| Zawisza, E | 3 |
| Reinholdt, J | 2 |
| Sparholt, SH | 1 |
| Alemán, A | 1 |
| Sastre, J | 1 |
| Quirce, S | 1 |
| de las Heras, M | 1 |
| Carnés, J | 1 |
| Fernández-Caldas, E | 1 |
| Pastor, C | 1 |
| Blázquez, AB | 1 |
| Vivanco, F | 1 |
| Cuesta-Herranz, J | 1 |
| Mierzwinski, J | 1 |
| Piziewicz, A | 1 |
| Bez, C | 1 |
| Schubert, R | 1 |
| Kopp, M | 1 |
| Ersfeld, Y | 1 |
| Berg, AV | 1 |
| Wahu, U | 1 |
| Krauth, MT | 1 |
| Reisinger, J | 1 |
| Pelzmann, M | 1 |
| Kronqvist, M | 1 |
| Grönlund, H | 1 |
| Suck, R | 2 |
| Fiebig, H | 2 |
| Cromwell, O | 2 |
| van Hage-Hamsten, M | 1 |
| Grindebacke, H | 1 |
| Wing, K | 1 |
| Andersson, AC | 1 |
| Suri-Payer, E | 1 |
| Rudin, A | 1 |
| Bolhaar, ST | 1 |
| Ree, R | 1 |
| Piotrowska, K | 1 |
| Cudowska, B | 1 |
| Kaczmarski, M | 1 |
| Oancea, I | 1 |
| Dahlgren, U | 1 |
| Gotlib, T | 1 |
| Grzanka, A | 1 |
| Johansson, S | 2 |
| Keen, C | 2 |
| Ståhl, A | 1 |
| Heinrich, C | 1 |
| Scheynius, A | 1 |
| Ricci, G | 1 |
| Righetti, F | 1 |
| Menna, G | 1 |
| Bellini, F | 1 |
| Miniaci, A | 1 |
| Masi, M | 1 |
| Shao, J | 1 |
| Luo, HY | 1 |
| Wedbäck, A | 1 |
| Enbom, H | 1 |
| Eriksson, NE | 1 |
| Malcus, I | 1 |
| Mittag, D | 1 |
| Wagner-Loew, D | 1 |
| Starke, A | 1 |
| Hunziker, P | 1 |
| Becker, WM | 1 |
| Süss, A | 1 |
| Rytter, M | 1 |
| Sticherling, M | 1 |
| Malm-Erjefält, M | 1 |
| Ankerst, J | 1 |
| Wallengren, J | 1 |
| Dehlink, E | 1 |
| Gerstmayr, M | 1 |
| Kampl, E | 1 |
| Chen, KW | 1 |
| Urbanek, R | 3 |
| Kihlström, A | 1 |
| Troye-Blomberg, M | 1 |
| Härfast, B | 1 |
| Winkler, B | 1 |
| Spittler, A | 1 |
| Ploder, M | 1 |
| Kállay, E | 1 |
| Renz, H | 1 |
| Nielsen, CH | 1 |
| Balenga, NA | 1 |
| Zahedifard, F | 1 |
| Weiss, R | 1 |
| Sarbolouki, MN | 1 |
| Rafati, S | 1 |
| Jacobsen, L | 6 |
| Dreborg, S | 3 |
| Ferdousi, HA | 3 |
| Halken, S | 3 |
| Høst, A | 3 |
| Koivikko, A | 4 |
| Koller, D | 1 |
| Norberg, LA | 3 |
| Möller, C | 3 |
| Carlsson, L | 1 |
| Guillot, G | 1 |
| Jernås, M | 1 |
| Langston, MA | 1 |
| Rudemo, M | 1 |
| Andersson, B | 1 |
| Ljørring, C | 1 |
| Savolainen, J | 3 |
| Albertini, R | 1 |
| Giordano, D | 1 |
| Soliani, L | 1 |
| Usberti, I | 1 |
| Dall'Aglio, PP | 1 |
| Alonso, R | 1 |
| Enrique, E | 1 |
| Pineda, F | 1 |
| Basagaña, M | 1 |
| San Miguel-Moncín, MM | 1 |
| Bartra, J | 1 |
| Palacios, R | 1 |
| Cisteró-Bahíma, A | 1 |
| Lund, L | 1 |
| Henmar, H | 1 |
| Hjortskov, N | 1 |
| Larsen, JN | 1 |
| Gazzola, GB | 1 |
| Di Cara, G | 1 |
| Frati, F | 1 |
| Nieminen, K | 1 |
| Laaksonen, K | 1 |
| Laiho, T | 1 |
| Lahesmaa, R | 1 |
| Terho, EO | 1 |
| Sommer, J | 1 |
| Stach, A | 2 |
| Peternel, R | 1 |
| Milanović, SM | 1 |
| Hrga, I | 1 |
| Mileta, T | 1 |
| Culig, J | 1 |
| Stenglein, S | 1 |
| Kasche, A | 1 |
| Klaus, S | 1 |
| Huss-Marp, J | 1 |
| Kramer, U | 1 |
| Fuhrman, C | 1 |
| Sarter, H | 1 |
| Delmas, MC | 1 |
| Zeghnoun, A | 1 |
| Lecadet, J | 1 |
| Yanai, M | 1 |
| Sato, K | 1 |
| Aoki, N | 1 |
| Takiyama, Y | 1 |
| Oikawa, K | 1 |
| Kobayashi, H | 1 |
| Kimura, S | 1 |
| Harabuchi, Y | 1 |
| Tateno, M | 1 |
| Weber, B | 1 |
| Wald, M | 1 |
| Adams-Groom, B | 1 |
| Maeda, Y | 1 |
| Ono, E | 1 |
| Turpeinen, AM | 1 |
| Ylönen, N | 1 |
| von Willebrand, E | 1 |
| Basu, S | 1 |
| Aro, A | 1 |
| Turner, S | 1 |
| Gunawan, H | 1 |
| Takai, T | 1 |
| Ikeda, S | 1 |
| Okumura, K | 1 |
| Ogawa, H | 1 |
| Koyanagi, Y | 1 |
| Watanabe, N | 1 |
| Jato, V | 1 |
| Rodríguez-Rajo, FJ | 1 |
| Aira, MJ | 1 |
| Bryborn, M | 1 |
| Halldén, C | 1 |
| Säll, T | 1 |
| Weber, JM | 1 |
| Piirainen, L | 1 |
| Haahtela, S | 1 |
| Helin, T | 1 |
| Korpela, R | 1 |
| Vaarala, O | 1 |
| Riediker, M | 1 |
| Monn, C | 1 |
| Koller, T | 1 |
| Stahel, WA | 1 |
| Koller, DY | 1 |
| Schauer, U | 1 |
| Leupold, W | 1 |
| Rolinck-Werninghaus, C | 1 |
| Gräve, M | 1 |
| Hultsch, T | 1 |
| Bødtger, U | 1 |
| Jacobi, HH | 1 |
| Vesterinen, E | 1 |
| Metso, T | 1 |
| Moneret-Vautrin, DA | 1 |
| Morisset, M | 1 |
| Lemerdy, P | 1 |
| Croizier, A | 1 |
| Kanny, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Subjects[NCT03969849] | Phase 1 | 96 participants (Actual) | Interventional | 2019-06-03 | Completed | ||
| Efficacy of Oral Tolerance Induction to Raw Apple Using an Ultra Rush Protocol in 28 Rosacea Allergic Patients[NCT04116580] | 28 participants (Actual) | Observational | 2016-06-01 | Completed | |||
| The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation[NCT02394600] | Phase 4 | 93 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass[NCT04296474] | Phase 1/Phase 2 | 34 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| Immune Response of Individuals Vaccinated With Hypoallergenic Derivatives of the Major Birch Pollen Allergen, Bet v 1[NCT01353924] | Phase 1 | 20 participants (Anticipated) | Interventional | 2011-08-31 | Not yet recruiting | ||
| A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Clinical Efficacy and Safety of SUBLIVAC FIX Birch Immunotherapy in Patients Suffering From Allergic Rhinitis/Rhinoconjunctivitis Caused by Birch Pollen.[NCT02231307] | Phase 3 | 406 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Acupuncture for Seasonal Allergic Rhinitis (ACUSAR) - A Randomised Controlled Trial[NCT00610584] | 422 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Perennial Allergic Rhinitis: a Randomized, Double-blind, Placebo Controlled Study[NCT04234451] | 40 participants (Anticipated) | Interventional | 2021-12-01 | Not yet recruiting | |||
| The Effects of Sphenopalatine Ganglion Acupuncture in Patients With Seasonal Allergic Rhinitis: A Randomized Trial[NCT03282630] | 150 participants (Actual) | Interventional | 2016-01-16 | Completed | |||
| Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Seasonal Allergic Rhinitis: a Randomized, Double-blind, Placebo Controlled Study[NCT04052945] | 70 participants (Anticipated) | Interventional | 2020-03-25 | Recruiting | |||
| A Double-blind, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Investigate the Efficacy, Tolerability, and Safety of Different Dosing Regimens of AZD8848 Administered Intranasally to Seasonal Allergic Rhinitis Patients Out of Pollen Sea[NCT01185080] | Phase 2 | 93 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| A Double-blind, Placebo Controlled, Randomized, Parallel Group Study to Investigate the Tolerability, Safety, Pharmacodynamics and Pharmacokinetics of Repeated Weekly Doses of AZD8848 Administered Intranasally to Seasonal Allergic Rhinitis Patients[NCT00770003] | Phase 1 | 103 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Birch in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Birch Pollen[NCT01639768] | Phase 2 | 270 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study[NCT03644680] | 36 participants (Actual) | Interventional | 2018-09-24 | Completed | |||
| Skin Testing With Recombinant Bet v 1 and Hypoallergenic Recombinant Bet v 1 Fragments to Dissect the Contribution of IgE to Chronic Allergic Skin Inflammation[NCT02098551] | 30 participants (Actual) | Observational | 2011-02-28 | Completed | |||
| The Molecular Biological Effects of Immunotherapy in the Nose[NCT01985542] | 16 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| Observation on the Efficacy of Sublingual Immunotherapy With Dust Mite Allergen for Perennial Allergic Rhinitis and the Mechanism of Action on ILCs With ILC1s and ILC2s and ILC3s[NCT05570383] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2022-12-01 | Not yet recruiting | ||
| The Diagnosis of Oral Allergy Syndrome Through the Use of a Structured Questionnaire[NCT00854958] | 123 participants (Actual) | Observational | 2005-05-31 | Completed | |||
| Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen: Monophosphoryl lipidA, Poly-inosine-cytosine, Poly-inosine-cytosine Stabilised With Poly-L-lysine and Carboxymethylcellulose, Resiquimod, Tuberculin and Timothy Gras[NCT02090374] | 93 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Phase I Study of Allergen-Specific Intralymphatic Immunotherapy in the United States[NCT01982474] | Phase 1 | 18 participants (Actual) | Interventional | 2013-10-31 | Active, not recruiting | ||
| Intralymphatic Immunotherapy in Increasing Doses up to 10 000 SQ-U -a Human Randomized Clinical Trial[NCT02679105] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma: A Randomized Placebo-controlled Trial[NCT03394508] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| The Efficacy and Adverse Effect of Intralymphatic Immunotherapy With Tyrosine S®, Allergen Extract for Immunotherapy, in Patients With Allergic Rhinitis Induced by House Dust Mite, Dog, and Cat Allergen[NCT02665754] | Phase 1 | 32 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Intra-lymphatic Immunotherapy for the Management of Peanut Allergy[NCT04200989] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2021-03-01 | Withdrawn (stopped due to Lack of funding) | ||
| Open-labeled Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients[NCT02301884] | Phase 1 | 12 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Double-blinded Placebo-controlled Randomized Clinical Trial Evaluating the Efficacy and Adverse Effect of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients[NCT02269566] | Phase 1 | 24 participants (Actual) | Interventional | 2014-08-31 | Terminated (stopped due to The number of enrolled subjects did not meet the goal during the study) | ||
| Local IgE in Subjects With Allergic or Non-allergic Rhinitis[NCT02810535] | 150 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| The Effects of Omalizumab on the Late-phase Response to Nasal Allergen Challenge[NCT01003301] | Phase 2 | 19 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Pilot Study of the Effect of Omalizumab on Basophil and Mast Responses to Intranasal Cat Allergen Challenge[NCT00604786] | 18 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To determine the effect of 4 months of treatment with Grastek® on the symptoms of birch pollen induced AR in participants with both timothy grass pollen-induced and birch pollen-induced allergen rhinitis (AR)~TNSS is comprised of the sum of 4 symptoms: runny nose, itchy nose sneezing and nasal congestion. Each of these symptoms are evaluated based on a 4 point Likert scale from 0-3. 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. TNSS can therefore have a range from 0 to 12." (NCT02394600)
Timeframe: 4 months
| Intervention | Scores on a scale (Mean) |
|---|---|
| Grastek | 2.3 |
| Placebo | 2.2 |
"Absolute mean value of Instantaneous Total Nasal Symptom Score (TNSS) for pre-dose symptoms on visit 2, during treatment period. Treatment period is one month, which starts at visit 2 and ends at visit 14. Each individual symptom is scored 0 to 3, which 0 = Absence of symptoms, 1 = Mild symptoms, 2 = Moderate symptoms and 3 = Severe symptoms. The scores of each individual symptom (runny nose, blocked nose and the maximum score of nasal itching or sneezing) will be added together to give a TNSS of 0 to 9. TNSS Score 0 indicates better outcome and TNSS score 9 indicate worse outcome.~Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data at visit 2." (NCT01185080)
Timeframe: Pre-dose on visit 2 (baseline)
| Intervention | Scores on a scale (Mean) |
|---|---|
| AZD8848 20 μg x3 | 0.38 |
| Placebo | 0.75 |
| AZD8848 60 μg | 0.35 |
"Absolute mean value of Instantaneous Total Nasal Symptom Score (TNSS) for pre-dose symptoms on visit11, during treatment period. Treatment period is one month, which starts at visit 2 and ends at visit 14. Each individual symptom is scored 0 to 3, which 0 = Absence of symptoms, 1 = Mild symptoms, 2 = Moderate symptoms and 3 = Severe symptoms. The scores of each individual symptom (runny nose, blocked nose and the maximum score of nasal itching or sneezing) will be added together to give a TNSS of 0 to 9. TNSS Score 0 indicates better outcome and TNSS score 9 indicates worse outcome.~Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data at visit 11." (NCT01185080)
Timeframe: Pre-dose on visit 11 (end of 3rd week of treatment)
| Intervention | Scores on a scale (Mean) |
|---|---|
| AZD8848 20 μg x3 | 1.20 |
| Placebo | 0.67 |
| AZD8848 60 μg | 0.80 |
"Absolute mean value of Peak Nasal Inspiratory Flow (PNIF) for pre-dose symptoms on visit 11, during treatment period. Treatment period is one month, which starts at visit 2 and ends at visit 14. The patient will breathe out as much as he can. Then a mask (Portable Inspiratory Flow Meter) will be placed over the nose and mouth and the patient will inspire forcefully through the nose while the lips remain tightly closed. The highest PNIF (L/minute) out of 3 measurements will be recorded.~Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data at visit 11." (NCT01185080)
Timeframe: Pre-dose on visit 11 (end of 3rd week of treatment)
| Intervention | L/min (Mean) |
|---|---|
| AZD8848 20 μg x3 | 168.1 |
| Placebo | 191.3 |
| AZD8848 60 μg | 182.7 |
"Absolute mean value of Peak Nasal Inspiratory Flow (PNIF) for pre-dose symptoms on visit 2, during treatment period. Treatment period is one month, which starts at visit 2 and ends at visit 14. The patient will breathe out as much as he can. Then a mask (Portable Inspiratory Flow Meter) will be placed over the nose and mouth and the patient will inspire forcefully through the nose while the lips remain tightly closed. The highest PNIF (L/minute) out of 3 measurements will be recorded.~Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data at visit 2." (NCT01185080)
Timeframe: Pre-dose on visit 2 (baseline)
| Intervention | L/min (Mean) |
|---|---|
| AZD8848 20 μg x3 | 170.4 |
| Placebo | 176.9 |
| AZD8848 60 μg | 169.4 |
"Change from baseline to 24 hours after last dose (day1 visit 15) of C-X-C motif chemokine 10 (CXCL10) in nasal lavage, expressed as a ratio. The ratio is calculated as day1 of visit 15 / baseline.~Number of Participants Analyzed is based on all patients with evaluable biomarker data at visit 2 and visit 15." (NCT01185080)
Timeframe: Baseline to 1st day of visit 15
| Intervention | ratio (Least Squares Mean) |
|---|---|
| AZD8848 20 μg x3 | 30.0 |
| Placebo | 1.66 |
| AZD8848 60 μg | 26.9 |
"Change from baseline to 24 hours after last dose (day1 visit 15) of C-X-C motif chemokine 10 (CXCL10) in plasma, expressed as a ratio. The ratio is calculated as day1 of visit 15 / baseline.~Number of Participants Analyzed is based on all patients with evaluable biomarker data at visit 2 and visit15." (NCT01185080)
Timeframe: Baseline to 1st day of visit 15
| Intervention | ratio (Geometric Mean) |
|---|---|
| AZD8848 20 μg x3 | 2.89 |
| Placebo | 0.803 |
| AZD8848 60 μg | 3.90 |
"Mean of evening measurements of Reflective Total Nasal Symptom Score (absolute values) of symptoms over the last 12 hours during allergen challenge, collected in patient diary. The Mean is calculated over the evening of the 1st day to the morning of 8th day of the Allergen challenge period. Each individual symptom is scored 0 to 3, which 0 = Absence of symptoms, 1 = Mild symptoms, 2 = Moderate symptoms and 3 = Severe symptoms. The scores of each individual symptom (runny nose, blocked nose and the maximum score of nasal itching or sneezing) will be added together to give a TNSS of 0 to 9. TNSS Score 0 indicates better outcome and TNSS score 9 indicates worse outcome.~Allergen challenge period starts 24 hrs post last dose. Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data from the challenge period (Visit 15)." (NCT01185080)
Timeframe: During the evening of the 1st day to the morning of the 8th day of Allergen challenge period.
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| AZD8848 20 μg x3 | 2.06 |
| Placebo | 2.32 |
| AZD8848 60 μg | 1.96 |
"Mean of morning measurements of Peak Nasal Inspiratory Flow (absolute values) of symptoms over the last 12 hours during allergen challenge, collected in patient diary. The Mean is calculated over the evening of the 1st day to the morning of 8th day of the Allergen challenge period. The patient will breathe out as much as he can. Then a mask (Portable Inspiratory Flow Meter) will be placed over the nose and mouth and the patient will inspire forcefully through the nose while the lips remain tightly closed. The highest PNIF (L/minute) out of 3 measurements will be recorded.~Allergen challenge period starts 24 hrs post last dose. Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data from the challenge period (Visit 15)." (NCT01185080)
Timeframe: During evening of the 1st day to the morning of the 8th day of Allergen challenge period.
| Intervention | L/min (Least Squares Mean) |
|---|---|
| AZD8848 20 μg x3 | 136 |
| Placebo | 148 |
| AZD8848 60 μg | 148 |
"Mean of morning measurements of Reflective Total Nasal Symptom Score (absolute values) of symptoms over the last 12 hours during allergen challenge, collected in patient diary. The Mean is calculated over the evening of the 1st day to the morning of 8th day of the Allergen challenge period. Each individual symptom is scored 0 to 3, which 0 = Absence of symptoms, 1 = Mild symptoms, 2 = Moderate symptoms and 3 = Severe symptoms. The scores of each individual symptom (runny nose, blocked nose and the maximum score of nasal itching or sneezing) will be added together to give a TNSS of 0 to 9. TNSS Score 0 indicates better outcome and TNSS score 9 indicates worse outcome.~Allergen challenge period starts 24 hrs post last dose. Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data from the challenge period (Visit 15)." (NCT01185080)
Timeframe: During evening of the 1st day to the morning of the 8th day of Allergen challenge period.
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| AZD8848 20 μg x3 | 1.81 |
| Placebo | 2.14 |
| AZD8848 60 μg | 1.48 |
"Mean of Peak Nasal Inspiratory Flow (absolute values) recorded immediately after TNSS scoring (recall period 10 min), during Allergen challenge period. The Mean is calculated over 4th day to 7th day of the Allergen challenge period. The patient will breathe out as much as he can. Then a mask (Portable Inspiratory Flow Meter) will be placed over the nose and mouth and the patient will inspire forcefully through the nose while the lips remain tightly closed. The highest PNIF (L/minute) out of 3 measurements will be recorded.~Allergen challenge period starts 24 hrs post last dose. Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data from the challenge period (Visit 15)." (NCT01185080)
Timeframe: During 4th day to 7th day of Allergen challenge period.
| Intervention | L/min (Least Squares Mean) |
|---|---|
| AZD8848 20 μg x3 | 121 |
| Placebo | 128 |
| AZD8848 60 μg | 135 |
"Mean of Peak Nasal Inspiratory Flow (absolute values) recorded immediately after TNSS scoring (recall period 10 min), during Allergen challenge period. The Mean is calculated over the Allergen challenge period, which is a seven day period. The patient will breathe out as much as he can. Then a mask (Portable Inspiratory Flow Meter) will be placed over the nose and mouth and the patient will inspire forcefully through the nose while the lips remain tightly closed. The highest PNIF (L/minute) out of 3 measurements will be recorded.~Allergen challenge period starts 24 hrs post last dose. Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data from the challenge period (Visit 15)." (NCT01185080)
Timeframe: During 1st day to 7th day of Allergen challenge period.
| Intervention | L/min (Least Squares Mean) |
|---|---|
| AZD8848 20 μg x3 | 117 |
| Placebo | 127 |
| AZD8848 60 μg | 129 |
"Mean of Reflective Total Nasal Symptom Score (absolute values) for symptoms over the last 10 minutes after allergen challenge, collected during clinic visits. The Mean is calculated over 4th day to 7th day of the Allergen challenge period. Each individual symptom is scored 0 to 3, which 0 = Absence of symptoms, 1 = Mild symptoms, 2 = Moderate symptoms and 3 = Severe symptoms. The scores of each individual symptom (runny nose, blocked nose and the maximum score of nasal itching or sneezing) will be added together to give a TNSS of 0 to 9. TNSS Score 0 indicates better outcome and TNSS score 9 indicates worse outcome. Allergen challenge period starts 24 hrs post last dose.~Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data from the challenge period (Visit 15)." (NCT01185080)
Timeframe: During 4th day to 7th day of Allergen challenge period.
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| AZD8848 20 μg x3 | 4.45 |
| Placebo | 5.36 |
| AZD8848 60 μg | 4.42 |
"Mean of Reflective Total Nasal Symptom Score (absolute values) for symptoms over the last 10 minutes after allergen challenge, collected during clinic visits. The Mean is calculated over the Allergen challenge period, which is a seven day period. Each individual symptom is scored 0 to 3, which 0 = Absence of symptoms, 1 = Mild symptoms, 2 = Moderate symptoms and 3 = Severe symptoms. The scores of each individual symptom (runny nose, blocked nose and the maximum score of nasal itching or sneezing) will be added together to give a TNSS of 0 to 9. TNSS Score 0 indicates better outcome and TNSS score 9 indicates worse outcome.~Allergen challenge period starts 24 hrs post last dose (visit 15). Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data from the challenge period (Visit 15)." (NCT01185080)
Timeframe: During 1st day to 7th day of Allergen challenge period.
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| AZD8848 20 μg x3 | 4.52 |
| Placebo | 4.97 |
| AZD8848 60 μg | 4.69 |
"Mean of evening measurements of Peak Nasal Inspiratory Flow (absolute values) of symptoms over the last 12 hours during allergen challenge, collected in patient diary. The Mean is calculated over the evening of the 1st day to the morning of 8th day of the Allergen challenge period. The patient will breathe out as much as he can. Then a mask (Portable Inspiratory Flow Meter) will be placed over the nose and mouth and the patient will inspire forcefully through the nose while the lips remain tightly closed. The highest PNIF (L/minute) out of 3 measurements will be recorded.~Allergen challenge period starts 24 hrs post last dose. Number of Participants Analyzed is based on all patients with evaluable efficacy and/or biomarker data from the challenge period (Visit 15)." (NCT01185080)
Timeframe: During evening of the 1st day to the morning of the 8th day of Allergen challenge period.
| Intervention | L/min (Least Squares Mean) |
|---|---|
| AZD8848 20 μg x3 | 145 |
| Placebo | 149 |
| AZD8848 60 μg | 147 |
"Visual analogue scale (VAS) was measured as 0-100 mm per each symptom question. VAS value 0 (mm) indicates no symptoms, and value 100 (mm) indicates the worst case.~Total VAS score = sum of the VAS scores for the 41 symptoms The minimum value of the total VAS score is 0, and the maximum value is 4100. Relative change = [(measure at time +6 months - measure at time -6 months)]/measure at time -6 months * 100%.~Measure = total VAS score" (NCT01985542)
Timeframe: -6 months vs. +6 months from the starting point of birch pollen subcutaneous immunotherapy.
| Intervention | percent change (Median) |
|---|---|
| Immunotherapy | -68 |
| No Immunotherapy | 91 |
"Transcriptomics are evaluated By Next Generation Sequencing. The total number of differentially expressed transcripts are defined from nasal epithelial brushing samples taken at -6 months vs. at +6 months in the two subject groups.~The subject groups are the Subcutaneous immunotherapy group and No immunotherapy group." (NCT01985542)
Timeframe: -6 months vs. +6 months from the starting point of birch pollen subcutaneous immunotherapy.
| Intervention | transcripts (Number) |
|---|---|
| Subcutaneous Immunotherapy | 119 |
| No Immunotherapy | 49 |
The primary outcome measure is IFN-y in nasal mucosal lining fluid after nasal challenge (NCT02090374)
Timeframe: 0, 1, 2, 3, 4, 6, 8 hours post-dose
| Intervention | pg/hr/ml (Mean) |
|---|---|
| Poly ICLC Dose Escalation | NA |
| Poly ICLC High Dose | 3.29 |
| Poly I:C Single Dose | 9.42 |
| R848 High Dose | 8.20 |
| R848 Low Dose | 5.10 |
| Grass Pollen | NA |
| Vitamin D Supplementation | NA |
| Tuberculin | NA |
Allergen-specific IgG and IgG4 level was measured by ImmunoCAP (Thermo Scientific, Uppsala, Sweden) for birch (t3) and timothy grass (g6) pollen according to the manufacturer's instructions. A cutoff 2 mg/L for IgG and 0.05 mg/L for IgG4 was considered positive. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | mg/L (Median) | |
|---|---|---|
| IgG after first season | IgG4 after first season | |
| Placebo | -0.25 | 0.03 |
Allergen-specific IgG and IgG4 level was measured by ImmunoCAP (Thermo Scientific, Uppsala, Sweden) for birch (t3) and timothy grass (g6) pollen according to the manufacturer's instructions. A cutoff 2 mg/L for IgG and 0.05 mg/L for IgG4 was considered positive. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | mg/L (Median) | |||
|---|---|---|---|---|
| IgG after first season | IgG4 after first season | IgG after second season compared to pre-treatment | IgG4 after second season compared to pre-treatment | |
| Active Treatment | 0.6 | 0.12 | -0.2 | 0 |
Allergen-specific IgE levels were measured by ImmunoCAP (Thermo Scientific, Uppsala, Sweden) for birch (t3) and timothy grass (g6) pollen according to the manufacturer's instructions. A cutoff level ≥ 0.35 kUA/L was considered positive. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | units on a scale IgE:Kua/L (Median) |
|---|---|
| IgE after first season | |
| Placebo | -0.5 |
Allergen-specific IgE levels were measured by ImmunoCAP (Thermo Scientific, Uppsala, Sweden) for birch (t3) and timothy grass (g6) pollen according to the manufacturer's instructions. A cutoff level ≥ 0.35 kUA/L was considered positive. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | units on a scale IgE:Kua/L (Median) | |
|---|---|---|
| IgE after first season | IgE after second season compared to pre-treatment | |
| Active Treatment | 10.5 | 0 |
Asthma control 4 weeks before follow-up was estimated with the asthma control test. The score is based on a questionnaire with 5 questions concerning the patients asthma. Each question can be given a score from 1 to 5 points. The answers for each question is added together, where a minimum score of 5 and a maximum score of 25 can be obtained. Higher scores indicate improved outcome and a score of 19 or less suggests poorly controlled asthma. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | score on a scale (Median) |
|---|---|
| After the first pollen seasonllen season | |
| Placebo | 0 |
Asthma control 4 weeks before follow-up was estimated with the asthma control test. The score is based on a questionnaire with 5 questions concerning the patients asthma. Each question can be given a score from 1 to 5 points. The answers for each question is added together, where a minimum score of 5 and a maximum score of 25 can be obtained. Higher scores indicate improved outcome and a score of 19 or less suggests poorly controlled asthma. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | score on a scale (Median) | |
|---|---|---|
| After the first pollen seasonllen season | After second season compared to pre-treatment | |
| Active Treatment | 0 | 1.5 |
FEV1 were measured according to international guidelines and results presented in % of predicted values according to the patients height, gender, age and weight. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | percent predicted FEV1 (Median) |
|---|---|
| After first season | |
| Placebo | -3 |
FEV1 were measured according to international guidelines and results presented in % of predicted values according to the patients height, gender, age and weight. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | percent predicted FEV1 (Median) | |
|---|---|---|
| After first season | After second season compared to pre-treatment | |
| Active Treatment | 1 | -5.5 |
Difference before and after treatment in Quality of Life. Quality of life was assessed using the Juniper Asthma Quality of Life Questionnaire, giving a score ranging from 1 to 7, and a change in score of 0.5 points is considered clinically relevant. Lower value is considered worse outcome. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | units on a scale (Median) |
|---|---|
| After first season | |
| Placebo | 0.17 |
Difference before and after treatment in Quality of Life. Quality of life was assessed using the Juniper Asthma Quality of Life Questionnaire, giving a score ranging from 1 to 7, and a change in score of 0.5 points is considered clinically relevant. Lower value is considered worse outcome. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | units on a scale (Median) | |
|---|---|---|
| After first season | After second season compared to pre-treatment | |
| Active Treatment | 0.3 | 0.13 |
Modified Symptom scores and Medication score were calculated taking into account the frequency: daily (4 points); every second day (3 points); 1 to 3 days per week (2 points); occasionally (1 point); never (0 points), for the following symptoms: blocked nose, rhinorrhea, fatigue, sneezing, and asthma symptoms, and for the following medications used: local and systemic antihistamines, nasal steroids, asthma medication, and eye drops. A minimum score of 0 and a maximum score of 20 points for symptoms and 16 points for medication could be obtained. Higher values indicate worse outcome. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | score on a scale (Median) | |
|---|---|---|
| Symptom score after first season | Medication score after first season | |
| Placebo | -3 | -2 |
Modified Symptom scores and Medication score were calculated taking into account the frequency: daily (4 points); every second day (3 points); 1 to 3 days per week (2 points); occasionally (1 point); never (0 points), for the following symptoms: blocked nose, rhinorrhea, fatigue, sneezing, and asthma symptoms, and for the following medications used: local and systemic antihistamines, nasal steroids, asthma medication, and eye drops. A minimum score of 0 and a maximum score of 20 points for symptoms and 16 points for medication could be obtained. Higher values indicate worse outcome. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | score on a scale (Median) | |||
|---|---|---|---|---|
| Symptom score after first season | Medication score after first season | Symptom score after second season | Medication score after second season | |
| Active Treatment | -4 | -2 | -5 | -3 |
0,1 ml of ALK Aquagen birch or timothy 10 000 SQU/ml is deposited in each nostril and allergy symptoms are recorded. Symptoms during NPTs were scored according to the Lebel scoring scale. Symtom scores at 5, 15, and 30 minutes after nasal administration of the allergenextract were summed to represent the symptom-score at each nasal challenge (at inclusion, 12 months after inclusion and for the active patients 24 months after inclusion). The scoring system identifies nasal, eye, and ear symptoms: rhinorrhea, nasal pruritus, nasal congestion, ocular pruritus, watery eyes, and itchy ears, each graded on a scale from 0 to 3 points, and a total score was summarized after subtracting the starting score (min score is 0 and maximum score is 54 + the number of sneezes). Higher scores mean worse outcome. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | score on a scale (Median) |
|---|---|
| After the first pollen season | |
| Placebo | -5 |
0,1 ml of ALK Aquagen birch or timothy 10 000 SQU/ml is deposited in each nostril and allergy symptoms are recorded. Symptoms during NPTs were scored according to the Lebel scoring scale. Symtom scores at 5, 15, and 30 minutes after nasal administration of the allergenextract were summed to represent the symptom-score at each nasal challenge (at inclusion, 12 months after inclusion and for the active patients 24 months after inclusion). The scoring system identifies nasal, eye, and ear symptoms: rhinorrhea, nasal pruritus, nasal congestion, ocular pruritus, watery eyes, and itchy ears, each graded on a scale from 0 to 3 points, and a total score was summarized after subtracting the starting score (min score is 0 and maximum score is 54 + the number of sneezes). Higher scores mean worse outcome. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | score on a scale (Median) | |
|---|---|---|
| After the first pollen season | After the second season compared to pre-treatment | |
| Active Treatment | -4 | -1 |
Treatment effect was evaluated by asking the patients to compare their allergic symptoms during the last pollen season with the pollen season before treatment on a visual analogue scale ranging from 0 (unchanged symptoms, no improvement) to 10 (total symptom relief, complete recovery). (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | score on a scale (Median) |
|---|---|
| After first season | |
| Placebo | 3.5 |
Treatment effect was evaluated by asking the patients to compare their allergic symptoms during the last pollen season with the pollen season before treatment on a visual analogue scale ranging from 0 (unchanged symptoms, no improvement) to 10 (total symptom relief, complete recovery). (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | score on a scale (Median) | |
|---|---|---|
| After first season | After second season compared to pre-treatment | |
| Active Treatment | 5.5 | 6.9 |
Nitric oxide in exhaled air, p.p.b. were measured according to international guidelines, and higher values indicate worse outcome. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | parts per billion (ppb) (Median) |
|---|---|
| After first season | |
| Placebo | -5 |
Nitric oxide in exhaled air, p.p.b. were measured according to international guidelines, and higher values indicate worse outcome. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | parts per billion (ppb) (Median) | |
|---|---|---|
| After first season | After second season compared to pre-treatment | |
| Active Treatment | 1 | -2.5 |
Methacholine challenge to test the bronchial hyperresponsiveness in the airways of the included subjects. The subject will inhale increasing doses of methacholine. Spirometry is performed before and between each inhalation. The cumulative dose of methacholine needed to elicit at 20% decrease in FEV1 (PD20) is reported. Lower values indicate worse outcome. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | units on a scale PD20 (Median) |
|---|---|
| After the first pollen season | |
| Placebo | -5 |
Methacholine challenge to test the bronchial hyperresponsiveness in the airways of the included subjects. The subject will inhale increasing doses of methacholine. Spirometry is performed before and between each inhalation. The cumulative dose of methacholine needed to elicit at 20% decrease in FEV1 (PD20) is reported. Lower values indicate worse outcome. (NCT03394508)
Timeframe: At inclusion (pre-treatment), 12 months after inclusion (after first pollen season) and for the active treated patients 24 months after inclusion (after the second pollen season).
| Intervention | units on a scale PD20 (Median) | |
|---|---|---|
| After the first pollen season | After the second pollen season compared to pre-tre | |
| Active Treatment | 23 | 53 |
Reduction in skin late phase size at 8 hours at the time of blood basophil hypo-responsiveness to allergen will be reduced compared to baseline. (NCT01003301)
Timeframe: Baseline, 2-6 wks
| Intervention | percentage decline from NAC-1 (Mean) |
|---|---|
| Omalizumab | 54 |
| Placebo | 0 |
"Flow cytometry in mean fluorescence units.~100%*[(3.5 month value minus baseline value)/baseline value]" (NCT00604786)
Timeframe: Change from baseline to 3.5 months
| Intervention | percentage of basophil surface IgE (Mean) |
|---|---|
| Omalizumab Subcutaneous | -95 |
| Placebo Subcutaneous | -10 |
10 reviews available for methyl salicylate and Hay Fever
| Article | Year |
|---|---|
Allergen immunotherapy for birch-apple syndrome: what do we know?
Topics: Antigens, Plant; Betula; Cross Reactions; Desensitization, Immunologic; Food Hypersensitivity; Human | 2017 |
Oral allergy syndrome.
Topics: Allergens; Ambrosia; Anaphylaxis; Animals; Betula; Eating; Food; Food Hypersensitivity; Humans; Poac | 2018 |
Birch pollen allergy in Europe.
Topics: Allergens; Antigens, Plant; Betula; Cross Reactions; Europe; Humans; Immunization; Immunoglobulin E; | 2019 |
[Birch pollen allergy].
Topics: Allergens; Betula; Environment; France; Humans; Pollen; Prevalence; Rhinitis, Allergic, Seasonal; Tr | 2014 |
Allergen immunotherapy for birch pollen-allergic patients: recent advances.
Topics: Animals; Antigens, Plant; Betula; Clinical Trials as Topic; Conjunctivitis, Allergic; Desensitizatio | 2016 |
Allergen interactions with epithelium.
Topics: Allergens; Betula; Biological Transport, Active; Cytokines; Gene Expression Profiling; Humans; Membr | 2011 |
Molecular diagnosis of fruit and vegetable allergy.
Topics: Allergens; Antigens, Plant; Betula; Diagnosis, Differential; Food Hypersensitivity; Fruit; Humans; I | 2011 |
Celery--cause of severe anaphylactic shock.
Topics: Adult; Allergens; Anaphylaxis; Apium; Betula; Cross Reactions; Female; Food Hypersensitivity; Humans | 2012 |
Exhaled nitric oxide in the diagnosis and management of asthma.
Topics: Adrenal Cortex Hormones; Asthma; Betula; Breath Tests; Child, Preschool; Clinical Trials as Topic; E | 2008 |
Food allergy and IgE sensitization caused by spices: CICBAA data (based on 589 cases of food allergy).
Topics: Adult; Anaphylaxis; Antibody Specificity; Artemisia; Betula; Comorbidity; Cross Reactions; Double-Bl | 2002 |
65 trials available for methyl salicylate and Hay Fever
| Article | Year |
|---|---|
Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial.
Topics: Allergens; Betula; Desensitization, Immunologic; Double-Blind Method; Humans; Immunotherapy; Plant E | 2023 |
A 5-Year Open-Label Follow-up of a Randomized Double-Blind Placebo-Controlled Trial of Intralymphatic Immunotherapy for Birch and Grass Allergy Reveals Long-term Beneficial Effects.
Topics: Allergens; Betula; Desensitization, Immunologic; Double-Blind Method; Follow-Up Studies; Humans; Imm | 2023 |
Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy.
Topics: Adult; Betula; Dendritic Cells; Desensitization, Immunologic; Female; Humans; Immune Tolerance; Immu | 2021 |
Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study.
Topics: Adult; Allergens; Antibodies, Monoclonal; Antigens, Plant; Basophils; Betula; Desensitization, Immun | 2022 |
Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
Topics: Administration, Cutaneous; Adolescent; Adult; Allergens; Antigens, Plant; Asthma; Betula; Child; Con | 2017 |
Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
Topics: Administration, Sublingual; Adolescent; Adult; Aged; Allergens; Betula; Biomarkers; Conjunctivitis, | 2018 |
Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy.
Topics: Adolescent; Adult; Allergens; Allergoids; Austria; Betula; Desensitization, Immunologic; Dose-Respon | 2018 |
Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Allergens; Betula; Conjunctivitis; Desensitization, Immunologic; Double-Blind Met | 2018 |
A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG
Topics: Adolescent; Adult; Aged; Betula; Conjunctivitis, Allergic; Female; Humans; Immunoglobulin E; Immunog | 2019 |
Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms.
Topics: Adolescent; Adult; Allergens; Antigens, Plant; Betula; Double-Blind Method; Female; Humans; Immunogl | 2019 |
Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
Topics: Adolescent; Adult; Aged; Allergens; Antigens, Plant; Asthma; Betula; Conjunctivitis, Allergic; Doubl | 2019 |
Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension.
Topics: Adolescent; Adult; Allergens; Area Under Curve; Betula; Desensitization, Immunologic; Female; Humans | 2019 |
The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial.
Topics: Adolescent; Adult; Aged; Allergens; Betula; Child; Conjunctivitis, Allergic; Double-Blind Method; Hu | 2019 |
Fast up-dosing with a birch allergoid is safe and well tolerated in allergic rhinitis patients with or without asthma.
Topics: Adolescent; Adult; Allergoids; Betula; Desensitization, Immunologic; Drug Administration Schedule; F | 2019 |
Birch pollen allergen immunotherapy reprograms nasal epithelial transcriptome and recovers microbial diversity.
Topics: Adult; Allergens; Betula; Desensitization, Immunologic; Female; Humans; Male; Middle Aged; Nasal Muc | 2019 |
Comprehensive profiling of peripheral immune cells and subsets in patients with intermittent allergic rhinitis compared to healthy controls and after treatment with glucocorticoids.
Topics: Adolescent; Adult; Basophils; Betula; Case-Control Studies; Eosinophils; Female; Glucocorticoids; Hu | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.
Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E; | 2013 |
Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.
Topics: Adolescent; Allergens; Betula; Child; Desensitization, Immunologic; Female; Humans; Male; Plant Extr | 2013 |
Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy.
Topics: Adult; Allergens; Antigens, Plant; Betula; Biomarkers; Desensitization, Immunologic; Double-Blind Me | 2015 |
Comparison of microneedles and adhesive-tape stripping in skin preparation for epicutaneous allergen delivery.
Topics: Administration, Cutaneous; Adolescent; Adult; Allergens; Betula; Desensitization, Immunologic; Femal | 2015 |
Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study.
Topics: Adenosine; Administration, Topical; Adolescent; Adult; Allergens; Anti-Allergic Agents; Betula; Cyto | 2015 |
Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study.
Topics: Adenosine; Administration, Topical; Adolescent; Adult; Allergens; Anti-Allergic Agents; Betula; Cyto | 2015 |
Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study.
Topics: Adenosine; Administration, Topical; Adolescent; Adult; Allergens; Anti-Allergic Agents; Betula; Cyto | 2015 |
Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study.
Topics: Adenosine; Administration, Topical; Adolescent; Adult; Allergens; Anti-Allergic Agents; Betula; Cyto | 2015 |
A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study.
Topics: Adolescent; Adult; Allergens; Betula; Desensitization, Immunologic; Female; Humans; Immune Tolerance | 2016 |
BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.
Topics: Adult; Antigens, Plant; Betula; Desensitization, Immunologic; Female; Food Hypersensitivity; Glycine | 2017 |
A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation.
Topics: Allergens; Antigen Presentation; Antigen-Presenting Cells; B-Lymphocytes; Betula; Desensitization, I | 2008 |
Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
Topics: Adult; Allergens; Anti-Allergic Agents; Betula; Conjunctivitis, Allergic; Desensitization, Immunolog | 2008 |
Immunological mechanisms in sublingual immunotherapy.
Topics: Administration, Sublingual; Adult; Allergens; Betula; Cross Reactions; Desensitization, Immunologic; | 2008 |
Specific probiotics alleviate allergic rhinitis during the birch pollen season.
Topics: Adolescent; Allergens; Betula; Bifidobacterium; Child; Child, Preschool; Cytokines; Double-Blind Met | 2009 |
Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
Topics: Adult; Antigens, CD; Antigens, Plant; Basophil Degranulation Test; Basophils; Betula; Desensitizatio | 2009 |
Early phase resolution of mucosal eosinophilic inflammation in allergic rhinitis.
Topics: Administration, Intranasal; Adult; Anti-Allergic Agents; Antigens, Plant; Apoptosis; Betula; Biopsy; | 2010 |
Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen.
Topics: Acetates; Administration, Sublingual; Adolescent; Adult; Aged; Antigens, Plant; Asthma; Betula; Cell | 2010 |
A randomized, double-blind, placebo-controlled exploratory study to evaluate the potential of pycnogenol for improving allergic rhinitis symptoms.
Topics: Adult; Anti-Allergic Agents; Betula; Double-Blind Method; Eye; Female; Flavonoids; Humans; Immunoglo | 2010 |
Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Betula; Child; Double-Blind Method; Female; Humans; Immunoglobulin E; Immunothera | 2010 |
Clinical trials with recombinant allergens--three perspectives: industry.
Topics: Allergens; Antigens, Plant; Betula; Desensitization, Immunologic; Drug Industry; Humans; Plant Prote | 2009 |
Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy.
Topics: Adult; Betula; Cell Separation; Corylus; Cross Reactions; Desensitization, Immunologic; Double-Blind | 2011 |
Strain-specific immunomodulatory effects of Lactobacillus plantarum strains on birch-pollen-allergic subjects out of season.
Topics: Adolescent; Adult; Allergens; Betula; Female; Humans; Interleukin-10; Lactobacillus plantarum; Male; | 2011 |
Birch pollen honey for birch pollen allergy--a randomized controlled pilot study.
Topics: Adult; Antigens, Plant; Betula; Conjunctivitis; Disease Progression; Female; Honey; Humans; Male; Pi | 2011 |
Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract--a new therapeutic option for patients with atopic dermatitis.
Topics: Adolescent; Adult; Aged; Betula; Cohort Studies; Dermatitis, Atopic; Female; Humans; Immunoglobulin | 2011 |
Development and validation of a structured questionnaire for the diagnosis of oral allergy syndrome in subjects with seasonal allergic rhinitis during the UK birch pollen season.
Topics: Adult; Aged; Algorithms; Betula; Cross Reactions; Double-Blind Method; Female; Food Hypersensitivity | 2011 |
A nasally applied cellulose powder in seasonal allergic rhinitis (SAR) in children and adolescents; reduction of symptoms and relation to pollen load.
Topics: Administration, Intranasal; Adolescent; Anti-Allergic Agents; Betula; Cellulose; Child; Double-Blind | 2011 |
Continuous apple consumption induces oral tolerance in birch-pollen-associated apple allergy.
Topics: Adolescent; Adult; Allergens; Betula; Cross Reactions; Desensitization, Immunologic; Female; Food Hy | 2012 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Topics: Adult; Allergens; Betula; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Double-Blind Met | 2013 |
Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis.
Topics: Adolescent; Adult; Allergens; alpha-Macroglobulins; Betula; Cross-Over Studies; Double-Blind Method; | 2002 |
The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
Topics: Adolescent; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B | 2002 |
Steroid-sensitive indices of airway inflammation in children with seasonal allergic rhinitis.
Topics: Administration, Topical; Adolescent; Allergens; alpha-Macroglobulins; Anti-Inflammatory Agents; Betu | 2003 |
Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study.
Topics: Administration, Sublingual; Adult; Allergens; Anti-Allergic Agents; Betula; Cross-Over Studies; Dese | 2004 |
A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation.
Topics: Allergens; Antigen Presentation; Antigens, Plant; Betula; Cells, Cultured; Desensitization, Immunolo | 2004 |
Allergy to kiwi: a double-blind, placebo-controlled food challenge study in patients from a birch-free area.
Topics: Actinidia; Adolescent; Adult; Allergens; Amino Acid Sequence; Betula; Beverages; Child; Child, Presc | 2004 |
Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis.
Topics: Adolescent; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B | 2004 |
Vaccination with genetically engineered allergens prevents progression of allergic disease.
Topics: Allergens; Betula; Cross Reactions; Double-Blind Method; Food; Humans; Hypersensitivity, Immediate; | 2004 |
The effect of specific immunotherapy on the expression of costimulatory molecules in late phase reaction of the skin in allergic patients.
Topics: Adult; Antigens, CD; B7-1 Antigen; B7-2 Antigen; Betula; CD28 Antigens; Desensitization, Immunologic | 2004 |
Comparison of nasal immunohistology in patients with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen immunotherapy.
Topics: Administration, Topical; Adult; Antigens, CD1; Betula; Biopsy; Conjunctivitis, Allergic; Desensitiza | 2005 |
Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis.
Topics: Adolescent; Allergens; Anti-Inflammatory Agents; Antibody Specificity; Antigens, Plant; Betula; Bude | 2005 |
Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.
Topics: Adolescent; Allergens; Antigens, Plant; Asthma; Betula; Child; Desensitization, Immunologic; Female; | 2006 |
Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Topics: Administration, Sublingual; Adolescent; Allergens; Alnus; Betula; Case-Control Studies; Child; Child | 2006 |
Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC.
Topics: Administration, Sublingual; Adolescent; Allergens; Alnus; Betula; Cells, Cultured; Child; Child, Pre | 2006 |
The type of sensitizing allergen can affect the evolution of respiratory allergy.
Topics: Adolescent; Adult; Allergens; Animals; Betula; Bronchial Hyperreactivity; Bronchial Provocation Test | 2006 |
Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study.
Topics: Administration, Cutaneous; Administration, Sublingual; Betula; Desensitization, Immunologic; Humans; | 2007 |
Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.
Topics: Adolescent; Adult; Allergens; Antigens, Plant; Asthma; Betula; Bronchial Provocation Tests; Desensit | 2007 |
Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy.
Topics: Administration, Sublingual; Adolescent; Allergens; Alnus; Antigens, CD; Betula; Cells, Cultured; Chi | 2007 |
Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects.
Topics: Adolescent; Allergens; Anti-Allergic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Ant | 2007 |
Immunological and metabolic effects of cis-9, trans-11-conjugated linoleic acid in subjects with birch pollen allergy.
Topics: Adult; Betula; Blood Cell Count; Blood Glucose; Cells, Cultured; Cytokines; Dietary Supplements; Fem | 2008 |
Effect of Lactobacillus rhamnosus GG on rBet v1 and rMal d1 specific IgA in the saliva of patients with birch pollen allergy.
Topics: Adolescent; Adult; Allergens; Antibody Specificity; Antigens, Plant; Betula; Double-Blind Method; Fe | 2008 |
Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).
Topics: Adolescent; Asthma; Betula; Bronchial Provocation Tests; Child; Conjunctivitis, Allergic; Desensitiz | 2002 |
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Topics: Adolescent; Anti-Allergic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Mo | 2002 |
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Topics: Adolescent; Anti-Allergic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Mo | 2002 |
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Topics: Adolescent; Anti-Allergic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Mo | 2002 |
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Topics: Adolescent; Anti-Allergic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Mo | 2002 |
The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study.
Topics: Adult; Allergens; Antibody Specificity; Betula; Conjunctivitis, Allergic; Desensitization, Immunolog | 2002 |
206 other studies available for methyl salicylate and Hay Fever
| Article | Year |
|---|---|
Birch pollen, air pollution and their interactive effects on airway symptoms and peak expiratory flow in allergic asthma during pollen season - a panel study in Northern and Southern Sweden.
Topics: Air Pollutants; Air Pollution; Asthma; Betula; Humans; Hypersensitivity; Particulate Matter; Pollen; | 2022 |
Patient-reported outcome measures in birch pollen allergic patients treated with sublingual immunotherapy reflect real life.
Topics: Allergens; Betula; Desensitization, Immunologic; Humans; Hypersensitivity; Patient Reported Outcome | 2023 |
Higher Risk for Sensitization to Commonly Consumed Herbs among Adults and Youngsters Suffering from Birch, Mugwort or Grass Pollinosis.
Topics: Adult; Allergens; Artemisia; Betula; Child; Cross Reactions; Food Hypersensitivity; Humans; Poaceae; | 2022 |
Pollen Sensitization Can Increase the Allergic Reaction to Non-Cross-Reactive Allergens in a Soy-Allergic Patient.
Topics: Allergens; Antigens, Plant; Betula; Cross Reactions; Food Hypersensitivity; Humans; Immunoglobulin E | 2023 |
Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development.
Topics: Adjuvants, Immunologic; Animals; Betula; CHO Cells; Cricetulus; Female; Immunotherapy; Lipid A; Male | 2019 |
Cinnamon extract inhibits allergen-specific immune responses in human and murine allergy models.
Topics: Acrolein; Animals; Basophils; Betula; CD4-Positive T-Lymphocytes; Cell Proliferation; Cinnamomum zey | 2020 |
Epidemiological study of oral allergy syndrome in birch pollen dispersal-free regions.
Topics: Adult; Allergens; Antigens, Plant; Betula; Cross Reactions; Female; Food Hypersensitivity; Fruit; Hu | 2020 |
Allergen-specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy.
Topics: Allergens; Betula; Desensitization, Immunologic; Food Hypersensitivity; Humans; Immunoglobulin E; Ma | 2020 |
Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study.
Topics: Adolescent; Adult; Aged; Betula; Female; Germany; Humans; Male; Middle Aged; Plant Extracts; Pollen; | 2020 |
Allergen immunotherapy for allergic rhinitis due to birch pollen? A tasty proposal!
Topics: Allergens; Betula; Desensitization, Immunologic; Humans; Pollen; Rhinitis, Allergic; Rhinitis, Aller | 2020 |
The development of birch pollen seasons over 30 years in Munich, Germany-An EAACI Task Force report.
Topics: Allergens; Betula; Germany; Humans; Pollen; Rhinitis, Allergic, Seasonal; Seasons | 2020 |
Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG
Topics: Allergens; Antibody Specificity; Basophils; Betula; Cell Degranulation; Endocytosis; Humans; Hyperse | 2020 |
Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy.
Topics: Adult; Allergens; Antigens, Plant; Betula; Desensitization, Immunologic; Epitope Mapping; Epitopes, | 2021 |
Identification of Seasonal Variations of Antibodies against PR-10-Specific Epitopes Can Be Improved Using Peptide-Phage Display.
Topics: Adult; Antigens, Plant; Betula; Cross Reactions; Epitope Mapping; Epitopes, B-Lymphocyte; Female; Ha | 2020 |
A new portable sampler to monitor pollen at street level in the environment of patients.
Topics: Allergens; Betula; Cities; Humans; Pollen; Rhinitis, Allergic, Seasonal | 2020 |
Allergenicity at component level of sub-pollen particles from different sources obtained by osmolar shock: A molecular approach to thunderstorm-related asthma outbreaks.
Topics: Allergens; Alnus; Ambrosia; Asthma; Betula; Cupressus; Disease Outbreaks; Enzyme-Linked Immunosorben | 2021 |
Simplified AIT for allergy to several tree pollens-Arguments from the immune outcome analyses following treatment with SQ tree SLIT-tablet.
Topics: Aesculus; Alnus; Basophil Degranulation Test; Betula; Betulaceae; Corylus; Cross Reactions; Fagus; H | 2021 |
Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice.
Topics: Adjuvants, Immunologic; Animals; Antigens, Plant; Asthma; Betula; Bronchoalveolar Lavage Fluid; Dise | 2021 |
Resolved allergen-specific IgE sensitization among females and early poly-sensitization among males impact IgE sensitization up to age 24 years.
Topics: Adolescent; Allergens; Animals; Antigens, Dermatophagoides; Artemisia; Betula; Cats; Child; Child, P | 2021 |
High-affinity Bet v 1-specific secretory IgA antibodies in nasal fluids protect against birch pollen allergy.
Topics: Allergens; Antigens, Plant; Betula; Humans; Hypersensitivity; Immunoglobulin A, Secretory; Plant Pro | 2021 |
Evaluation of safety and tolerability of a rush up-dosing allergen-specific immunotherapy with grass pollen, birch, hazel, and alder allergoid in children with allergic rhinoconjunctivitis, with or without asthma.
Topics: Allergens; Allergoids; Alnus; Asthma; Betula; Child; Humans; Poaceae; Pollen; Rhinitis, Allergic, Se | 2021 |
Depletion of CD56
Topics: Allergens; Animals; Betula; CD3 Complex; CD56 Antigen; Colitis; Colon; Female; Humans; Immunoglobuli | 2021 |
Primary and pollen-associated hazelnut allergy in school-aged children in Germany: A birth cohort study.
Topics: Allergens; Antigens, Plant; Betula; Child; Corylus; Female; Germany; Humans; Male; Nut Hypersensitiv | 2021 |
Environmental exposure unit simulates natural seasonal birch pollen exposures while maximizing change in allergic symptoms.
Topics: Adult; Allergens; Anti-Allergic Agents; Betula; Cetirizine; Environmental Exposure; Female; Humans; | 2021 |
Case Report: Safe and Effective Sublingual Birch Allergen Immunotherapy in Two HIV-Positive Patients.
Topics: Administration, Sublingual; Adult; Allergens; Betula; Desensitization, Immunologic; Drug-Related Sid | 2021 |
Analysis of changes in Betula pollen season start including the cycle of pollen concentration in atmospheric air.
Topics: Allergens; Betula; Environmental Monitoring; Pollen; Rhinitis, Allergic, Seasonal; Seasons; Temperat | 2021 |
Spatial distribution of allergenic pollen through a large metropolitan area.
Topics: Air Pollutants; Allergens; Betula; Cities; Environmental Monitoring; Europe; Germany; Humans; Hypers | 2017 |
The Clinical Impact of Bet v 6 in Birch Pollen-Sensitized Patients.
Topics: Adolescent; Adult; Allergens; Antigens, Plant; Betula; Female; Humans; Immunoglobulin E; Male; Middl | 2017 |
The TLR4-TRIF pathway can protect against the development of experimental allergic asthma.
Topics: Adaptor Proteins, Vesicular Transport; Adoptive Transfer; Animals; Antigens, Plant; Asthma; Betula; | 2017 |
Critical role of mammalian target of rapamycin for IL-10 dendritic cell induction by a flagellin A conjugate in preventing allergic sensitization.
Topics: Allergens; Animals; Antigens, Plant; Betula; Bone Marrow; CD4-Positive T-Lymphocytes; Cytokines; Den | 2018 |
Birch pollen-related foods can cause late eczematous reactions in patients with atopic dermatitis.
Topics: Adult; Betula; Child; Dermatitis, Atopic; Double-Blind Method; Eczema; Female; Food Hypersensitivity | 2018 |
A novel role for neutrophils in IgE-mediated allergy: Evidence for antigen presentation in late-phase reactions.
Topics: Allergens; Antigen Presentation; Betula; Cytokines; Humans; Hypersensitivity; Immunoglobulin E; Neut | 2019 |
Effect of the Strawberry Genotype, Cultivation and Processing on the Fra a 1 Allergen Content.
Topics: Antigens, Plant; Betula; Cold Temperature; Crop Production; Cross Reactions; Desiccation; Enzyme-Lin | 2018 |
Uptake of ozone and modification of lipids in Betula Pendula pollen.
Topics: Air Pollutants; Allergens; Betula; Lipids; Ozone; Pollen; Rhinitis, Allergic, Seasonal | 2018 |
Mal d 1 and Bet v 1 sensitization pattern in children with Pollen Food Syndrome.
Topics: Adolescent; Allergens; Antigens, Plant; Betula; Child; Child, Preschool; Cross Reactions; Female; Fo | 2019 |
Birch pollen-specific subcutaneous immunotherapy reduces ILC2 frequency but does not suppress IL-33 in mice.
Topics: Allergens; Animals; Betula; Bronchoalveolar Lavage Fluid; Cytokines; Desensitization, Immunologic; D | 2018 |
Neutrophils promote T-cell-mediated inflammation in allergy.
Topics: Allergens; Animals; Asthma; Betula; Cells, Cultured; Disease Models, Animal; Humans; Inflammation; L | 2019 |
Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen.
Topics: Animals; Antigens, Plant; Betula; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoglobulin | 2019 |
Chinese Birch Pollen Allergy and Immunotherapy in Mice.
Topics: Animals; Betula; China; HSP70 Heat-Shock Proteins; Immunotherapy; Inflammation; Mass Spectrometry; M | 2019 |
Birch pollen allergen-specific immunotherapy with glutaraldehyde-modified allergoid induces IL-10 secretion and protective antibody responses.
Topics: Allergens; Allergoids; Antibody Formation; Antigens, Plant; Betula; Glutaral; Humans; Immunity, Cell | 2019 |
Cashew Tree Pollen: An Unknown Source of IgE-Reactive Molecules.
Topics: Adolescent; Adult; Aged; Allergens; Anacardium; Animals; Antigens, Plant; Betula; Brazil; Carrier Pr | 2019 |
A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Topics: Allergens; Animals; Antigen Presentation; Antigens, Plant; Betula; Cross Reactions; Epitopes, T-Lymp | 2013 |
The influence of sensitisation to pollens and moulds on seasonal variations in asthma attacks.
Topics: Adult; Allergens; Alternaria; Asthma; Betula; Europe; Female; Follow-Up Studies; Fungi; Humans; Immu | 2013 |
Characterisation of CD154+ T cells following ex vivo birch allergen stimulation defines a close relationship between T cell subsets in healthy volunteers.
Topics: Adult; Allergens; Betula; CD40 Ligand; Cell Differentiation; Cytokines; Epitopes; Female; Health; Hu | 2013 |
Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma.
Topics: Administration, Sublingual; Allergens; Animals; Antigens, Plant; Asthma; Betula; Bronchial Hyperreac | 2013 |
Component-resolved diagnosis of peach allergy and its relationship with prevalent allergenic pollens in China.
Topics: Adolescent; Adult; Allergens; Artemisia; Betula; Child; Child, Preschool; China; Female; Food Hypers | 2013 |
IgG antibodies in food allergy influence allergen-antibody complex formation and binding to B cells: a role for complement receptors.
Topics: Adolescent; Adult; Aged; Allergens; Animals; Antigen-Antibody Complex; B-Lymphocytes; Betula; Cell L | 2013 |
An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy.
Topics: Adult; Allergens; Antibody Specificity; Antigens, Plant; Betula; Desensitization, Immunologic; Femal | 2013 |
Effects of airborne birch pollen levels on clinical symptoms of seasonal allergic rhinoconjunctivitis.
Topics: Adult; Air Pollutants; Allergens; Betula; Conjunctivitis, Allergic; Female; Humans; Male; Middle Age | 2014 |
Carrying peptides towards the ideal allergen-specific immunotherapy.
Topics: Animals; Antibodies, Neutralizing; Antigens, Plant; Betula; Epitopes, T-Lymphocyte; Female; Peptides | 2014 |
Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy.
Topics: Adjuvants, Immunologic; Aluminum Hydroxide; Animals; Antibodies, Neutralizing; Antigens, Plant; Betu | 2014 |
[Oral allergy syndrome in patients with pollen allergy].
Topics: Adolescent; Adult; Allergens; Betula; Child; Cross Reactions; Female; Food Hypersensitivity; Humans; | 2013 |
[A three year survey of the practical application of pollen monitoring in specific allergen immunotherapy].
Topics: Allergens; Betula; Desensitization, Immunologic; Environmental Exposure; Environmental Monitoring; H | 2013 |
Immunologic response and safety in birch pollen sublingual versus oral vestibule immunotherapy: a pilot study.
Topics: Administration, Oral; Administration, Sublingual; Allergens; Betula; Desensitization, Immunologic; H | 2014 |
Parental hay fever reinforces IgE to pollen as pre-clinical biomarker of hay fever in childhood.
Topics: Adolescent; Allergens; Antigens, Plant; Betula; Biomarkers; Child; Child of Impaired Parents; Child, | 2014 |
[A relationship between birch pollen counts and meteorological factors in Sapporo].
Topics: Allergens; Betula; Humans; Japan; Photoperiod; Pollen; Rhinitis, Allergic, Seasonal; Seasons; Weathe | 2014 |
Bet v 1--a Trojan horse for small ligands boosting allergic sensitization?
Topics: Allergens; Animals; Antigens, Plant; Basophil Degranulation Test; Basophils; Betula; Cell Degranulat | 2014 |
Effects of atmospheric pollutants (CO, O3, SO2) on the allergenicity of Betula pendula, Ostrya carpinifolia, and Carpinus betulus pollen.
Topics: Air Pollutants; Animals; Betula; Betulaceae; Carbon Monoxide; Electrophoresis, Polyacrylamide Gel; H | 2015 |
[Anaphylactic reaction after peanut intake in a patient with birch pollen allergy].
Topics: Anaphylaxis; Betula; Diagnosis, Differential; Humans; Immunoglobulin E; Intradermal Tests; Male; Mid | 2015 |
Topical dsRNA challenges may induce overexpression of airway antiviral cytokines in symptomatic allergic disease. A pilot in vivo study in nasal airways.
Topics: Adult; Betula; Cytokines; Female; Gene Expression Profiling; Humans; Male; Nasal Cavity; Nasal Mucos | 2014 |
Pollen grains as allergenic environmental factors--new approach to the forecasting of the pollen concentration during the season.
Topics: Betula; Cities; Environmental Exposure; Environmental Monitoring; Humans; Logistic Models; Models, B | 2014 |
Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cells.
Topics: Allergens; Antigen-Presenting Cells; Antigens, Surface; Betula; Biomarkers; Biopsy; Case-Control Stu | 2015 |
Component-resolved IgE profiles in Austrian patients with a convincing history of peanut allergy.
Topics: 2S Albumins, Plant; Adolescent; Adult; Allergens; Antigens, Plant; Arachis; Austria; Betula; Case-Co | 2015 |
Can we improve pollen season definitions by using the symptom load index in addition to pollen counts?
Topics: Air Pollutants; Allergens; Austria; Betula; Humans; Poaceae; Pollen; Rhinitis, Allergic, Seasonal; S | 2015 |
Allergic rhinitis and voice change.
Topics: Acoustics; Adult; Betula; Case-Control Studies; Edema; Female; Humans; Male; Middle Aged; Pollen; Pr | 2016 |
Defining thresholds of specific IgE levels to grass pollen and birch pollen allergens improves clinical interpretation.
Topics: Allergens; Betula; Female; Fluoroimmunoassay; Humans; Immunoenzyme Techniques; Immunoglobulin E; Mal | 2015 |
Can serum white birch (Betula verrucosa) pollen antigen (Bet v 1) immunoglobulin E measurement distinguish between sensitization and allergy?
Topics: Adult; Allergens; Antigens, Plant; Betula; Cross Reactions; Diagnosis, Differential; Female; Humans; | 2015 |
Recombinant Mal d 1 facilitates sublingual challenge tests of birch pollen-allergic patients with apple allergy.
Topics: Administration, Sublingual; Adult; Allergens; Antigens, Plant; Betula; Female; Food Hypersensitivity | 2016 |
Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.
Topics: Adult; Allergens; Antigens, Plant; Betula; Cytokines; Dermatitis, Atopic; Female; Histamine Release; | 2016 |
Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.
Topics: Adult; Allergens; Antigens, Plant; Betula; Cytokines; Dermatitis, Atopic; Female; Histamine Release; | 2016 |
Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.
Topics: Adult; Allergens; Antigens, Plant; Betula; Cytokines; Dermatitis, Atopic; Female; Histamine Release; | 2016 |
Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.
Topics: Adult; Allergens; Antigens, Plant; Betula; Cytokines; Dermatitis, Atopic; Female; Histamine Release; | 2016 |
Pimecrolimus Is a Potent Inhibitor of Allergic Reactions to Hymenopteran Venom Extracts and Birch Pollen Allergen In Vitro.
Topics: Adult; Aged; Allergens; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2015 |
[Oral Allergy Syndrome Following Soy Milk Ingestion in Patients with Birch Pollen Allergy].
Topics: Adolescent; Adult; Aged; Betula; Child; Child, Preschool; Cross Reactions; Female; Food Hypersensiti | 2015 |
Exhaled particles as markers of small airway inflammation in subjects with asthma.
Topics: Adult; Aerosols; Asthma; Betula; Biomarkers; Breath Tests; Exhalation; Female; Humans; Lung; Male; M | 2017 |
Persistence of the IgE repertoire in birch pollen allergy.
Topics: Antigens, Plant; Betula; Female; High-Throughput Nucleotide Sequencing; Humans; Immunoglobulin E; Mi | 2016 |
Pollen derived low molecular compounds enhance the human allergen specific immune response in vivo.
Topics: Allergens; Basophils; Betula; Cell Degranulation; Humans; Immunity; Immunoglobulin E; Immunomodulati | 2016 |
High correlation of specific IgE sensitization between birch pollen, soy and apple allergens indicates pollen-food allergy syndrome among birch pollen allergic patients in northern China.
Topics: Adolescent; Adult; Aged; Allergens; Antigens, Plant; Betula; Child; Child, Preschool; China; Food Hy | 2016 |
Oocyst-Derived Extract of Toxoplasma Gondii Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy.
Topics: Allergens; Animals; Antigens, Plant; Betula; Female; Humans; Hypersensitivity; Hypersensitivity, Imm | 2016 |
Profiles of Birch Sensitization (Bet v 1, Bet v 2, and Bet v 4) and Oral Allergy Syndrome Across Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Plant; Betula; Calcium-Binding Proteins; Femal | 2016 |
The clinical relevance of birch pollen profilin cross-reactivity in sensitized patients.
Topics: Adolescent; Adult; Allergens; Antibody Specificity; Basophils; Betula; Cross Reactions; Female; Huma | 2017 |
The dynamics of the Corylus, Alnus, and Betula pollen seasons in the context of climate change (SW Poland).
Topics: Allergens; Alnus; Betula; Climate Change; Corylus; Poland; Pollen; Rhinitis, Allergic, Seasonal; Sea | 2016 |
Allergy to apple cultivars among patients with birch pollinosis and oral allergy syndrome.
Topics: Adult; Aged; Allergens; Antigens, Plant; Betula; Cross Reactions; Female; Food Hypersensitivity; Fru | 2016 |
Patching it together: epicutaneous vaccination with heat-labile Escherichia coli toxin against birch pollen allergy.
Topics: Betula; Enterotoxins; Escherichia coli; Hot Temperature; Humans; Pollen; Rhinitis, Allergic, Seasona | 2017 |
Clinical benefit of component-resolved diagnosis in Japanese birch-allergic patients with a convincing history of apple or peach allergy.
Topics: Adolescent; Adult; Aged; Antigens, Plant; Betula; Female; Food Hypersensitivity; Humans; Immunoglobu | 2017 |
Potential Involvement of Type I Interferon Signaling in Immunotherapy in Seasonal Allergic Rhinitis.
Topics: Adult; Betula; Cells, Cultured; Female; Humans; Immunotherapy; Interferon-alpha; Interferon-beta; In | 2016 |
The Impact on Allergy-Related Cells of a Birch Pollen Allergoid, with and without Monophosphoryl Lipid A, in Comparison with the Native Equivalent.
Topics: Adjuvants, Immunologic; Allergens; Allergoids; Basophils; Betula; Cells, Cultured; Desensitization, | 2017 |
Bariatric Surgery: A Novel Risk Factor for Food Allergy?
Topics: Angioedema; Betula; Dyspnea; Female; Food Hypersensitivity; Fruit; Gastric Bypass; Humans; Immunoglo | 2017 |
Serum IL-17 levels in patients with allergic rhinitis.
Topics: Adult; Betula; Female; Humans; Interleukin-17; Male; Pollen; Rhinitis, Allergic, Seasonal; T-Lymphoc | 2008 |
[Fifty percent of pollinosis patients sensitive to birch pollen demonstrate bronchoconstriction during bronchial provocation test with the allergen].
Topics: Adolescent; Adult; Allergens; Betula; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronch | 2008 |
Simultaneous flow cytometric detection of basophil activation marker CD63 and intracellular phosphorylated p38 mitogen-activated protein kinase in birch pollen allergy.
Topics: Antigens, Plant; Basophils; Betula; Case-Control Studies; Enzyme Activation; Flow Cytometry; Humans; | 2009 |
[Clustering of food causing oral allergy syndrome in patients with birch pollen allergy].
Topics: Adolescent; Adult; Aged; Betula; Cluster Analysis; Female; Food; Food Hypersensitivity; Humans; Male | 2008 |
Are the birch trees in Southern England a source of Betula pollen for North London?
Topics: Air Movements; Betula; England; Humans; London; Pollen; Rhinitis, Allergic, Seasonal; Time Factors | 2009 |
High risk of immediate-type reactions to soy drinks in 50 patients with birch pollinosis.
Topics: Adult; Betula; Cross Reactions; Female; Food Hypersensitivity; Humans; Immunoglobulin E; Male; Middl | 2008 |
Serum interleukin-17 levels are related to clinical severity in allergic rhinitis.
Topics: Adult; Allergens; Betula; Cell Count; Eosinophils; Female; Humans; Interleukin-17; Male; Pollen; Rhi | 2009 |
Contrast medium and patients at risk: asthma.
Topics: Allergens; Asthma; Betula; Contrast Media; Drug Eruptions; Drug Hypersensitivity; Humans; Iohexol; M | 2009 |
High throughput screening of mixed-mode sorbents and optimisation using pre-packed lab-scale columns for the purification of the recombinant allergen rBet v 1a.
Topics: Allergens; Betula; Chromatography, Liquid; Humans; Pollen; Recombinant Proteins; Resins, Synthetic; | 2009 |
The human eosinophil proteome. Changes induced by birch pollen allergy.
Topics: Allergens; Amino Acid Sequence; Betula; Cofilin 1; Cytoskeletal Proteins; Electrophoresis, Gel, Two- | 2009 |
Two year sublingual immunotherapy affects serum leptin.
Topics: Administration, Sublingual; Adolescent; Adult; Aged; Allergens; Betula; Cohort Studies; Desensitizat | 2009 |
Effect of natural seasonal pollen exposure and repeated nasal allergen provocations on elevation of exhaled nitric oxide.
Topics: Administration, Intranasal; Allergens; Asthma; Betula; Eosinophils; Exhalation; Forced Expiratory Vo | 2009 |
Eosinophil cationic protein (ECP) is processed during secretion.
Topics: Betula; Case-Control Studies; Eosinophil Cationic Protein; Eosinophils; Glycosylation; Humans; Mass | 2009 |
Reported symptoms to peanut between 4 and 8 years among children sensitized to peanut and birch pollen - results from the BAMSE birth cohort.
Topics: Betula; Child; Child, Preschool; Cohort Studies; Cross Reactions; Humans; Immunoglobulin E; Peanut H | 2010 |
Time-series nasal epithelial transcriptomics during natural pollen exposure in healthy subjects and allergic patients.
Topics: Adult; Betula; Female; Gene Expression Profiling; Humans; Male; Mast Cells; Nasal Mucosa; Pollen; Rh | 2010 |
Association of allergic patients' phenotypes with IgE reactivity to recombinant pollen marker allergens.
Topics: Adult; Allergens; Betula; Cross Reactions; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immuno | 2010 |
Allergen provocation increases TH2-cytokines and FOXP3 expression in the asthmatic lung.
Topics: Adult; Allergens; Asthma; Betula; Bronchial Provocation Tests; Bronchoalveolar Lavage; Bronchoalveol | 2010 |
Food-dependent exercise-induced anaphylaxis in the celery-mugwort-birch-spice syndrome.
Topics: Adolescent; Anaphylaxis; Apium; Artemisia; Asthma, Exercise-Induced; Betula; Food Hypersensitivity; | 2010 |
Peripheral Th-17 cells in allergic rhinitis: New evidence.
Topics: Adult; Allergens; Antigens, Dermatophagoides; Betula; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-P | 2010 |
Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
Topics: Allergens; Asthma; Betula; Cell Differentiation; Cells, Cultured; Coculture Techniques; Desensitizat | 2010 |
Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antigens, Plant; Artemisia; Betula; Disease Progression; Eosi | 2009 |
Simultaneous SCIT with 2 separate allergen extracts demonstrates comparable safety compared to SCIT with a single allergen extract.
Topics: Allergens; Betula; Desensitization, Immunologic; Humans; Immunoglobulin E; Injections, Subcutaneous; | 2009 |
The allergen Bet v 1 in fractions of ambient air deviates from birch pollen counts.
Topics: Air; Antigens, Plant; Betula; Environmental Monitoring; Enzyme-Linked Immunosorbent Assay; Germany; | 2010 |
Naturally processed T cell-activating peptides of the major birch pollen allergen.
Topics: Antigen Presentation; Antigens, Plant; Betula; CD4-Positive T-Lymphocytes; Dendritic Cells; Epitopes | 2010 |
IgE to peanut allergen components: relation to peanut symptoms and pollen sensitization in 8-year-olds.
Topics: 2S Albumins, Plant; Antigens, Plant; Arachis; Betula; Child; Cohort Studies; Cross Reactions; Female | 2010 |
Anaphylaxis after consuming soy products in patients with birch pollinosis.
Topics: Anaphylaxis; Antigens, Plant; Betula; Cross Reactions; Food Hypersensitivity; Humans; Rhinitis, Alle | 2010 |
Serum interleukin 9 in allergic rhinitis.
Topics: Antigens, Plant; Betula; Biomarkers; Cross Reactions; Disease Progression; Humans; Interleukin-9; Na | 2010 |
[What the general practitioner should know about food allergy].
Topics: Allergens; Anaphylaxis; Betula; Cross Reactions; Food Hypersensitivity; Humans; Immunoglobulin E; Rh | 2010 |
Allergens are transported through the respiratory epithelium.
Topics: Allergens; Betula; Biological Transport; Case-Control Studies; Caveolae; Cell Membrane Permeability; | 2010 |
Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
Topics: Administration, Sublingual; Allergens; Animals; Antigens, Plant; Betula; Clinical Trials as Topic; D | 2010 |
Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy.
Topics: Adolescent; Adult; Allergens; Basophils; Betula; Cell Separation; Desensitization, Immunologic; Fema | 2010 |
Bet v 1 and its homologous food allergen Api g 1 stimulate dendritic cells from birch pollen-allergic individuals to induce different Th-cell polarization.
Topics: Adult; Allergens; Antigens, Plant; Betula; Cell Polarity; Cells, Cultured; Coculture Techniques; Cro | 2010 |
Tracing antigen signatures in the human IgE repertoire.
Topics: Allergens; Antibody Specificity; Antigens, Plant; Base Sequence; Betula; DNA Primers; Genes, Immunog | 2010 |
Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly.
Topics: Animals; Antigens, Plant; Betula; Enzyme-Linked Immunosorbent Assay; Epitopes, T-Lymphocyte; Humans; | 2010 |
Nasal application of rBet v 1 or non-IgE-reactive T-cell epitope-containing rBet v 1 fragments has different effects on systemic allergen-specific antibody responses.
Topics: Administration, Intranasal; Adult; Allergens; Antibody Formation; Antigens, Plant; Betula; Desensiti | 2010 |
[Relationship between IgE antibodies to recombinant allergens rBet v 1 and rBet v 2 and food causing oral allergy syndrome in cases of birch-pollen allergy].
Topics: Adolescent; Adult; Aged; Antibodies; Antigens, Plant; Apraxias; Betula; Child; Cross Reactions; Fema | 2010 |
Lactobacillus strains differentially modulate cytokine production by hPBMC from pollen-allergic patients.
Topics: Antigens, Plant; Betula; Cell Death; Cell Proliferation; Cytokines; Gene Expression Profiling; Gene | 2011 |
Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
Topics: Allergens; Animals; Antibody Formation; Antibody Specificity; Antigens, Plant; Betula; Cloning, Mole | 2011 |
Distinctive anti-allergy properties of two probiotic bacterial strains in a mouse model of allergic poly-sensitization.
Topics: Animals; Betula; Bifidobacterium; Female; Immunologic Factors; Lactobacillus; Mice; Mice, Inbred BAL | 2011 |
[Severe bronchospasm using Diprivan® in a patient allergic to peanut and birch].
Topics: Anesthesia, General; Asthma; Betula; Bronchial Spasm; Child; Drug Hypersensitivity; Humans; Hypnotic | 2011 |
Allergen-induced accumulation of CD68-,CD123+ dendritic cells in the nasal mucosa.
Topics: Adjuvants, Immunologic; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Pl | 2011 |
They tell me I'm allergic to ragweed.
Topics: Allergens; Ambrosia; Betula; Humans; Immunoglobulin E; Poaceae; Rhinitis, Allergic, Seasonal; Sensit | 2011 |
A prospective, clinical study on asymptomatic sensitisation and development of allergic rhinitis: high negative predictive value of allergological testing.
Topics: Adult; Allergens; Betula; Denmark; Female; Humans; Immunoglobulin E; Incidence; Male; Middle Aged; P | 2011 |
Allergen-specific immunotherapy with recombinant allergens.
Topics: Antigens, Plant; Asthma; Betula; Clinical Trials as Topic; Desensitization, Immunologic; Humans; Hyp | 2011 |
Freezing does not alter antigenic properties of fresh fruits for skin testing in patients with birch tree pollen-induced oral allergy syndrome.
Topics: Adult; Allergens; Antigens, Plant; Betula; Case-Control Studies; Female; Food Hypersensitivity; Free | 2011 |
Reshaping the Bet v 1 fold modulates T(H) polarization.
Topics: Allergens; Amino Acid Sequence; Animals; Antigen-Antibody Reactions; Antigens, Plant; Betula; Cell P | 2011 |
[Anaphylactic reaction after soya intake in a patient with birch pollen allergy].
Topics: Aged; Anaphylaxis; Betula; Comorbidity; Diagnosis, Differential; Food Hypersensitivity; Humans; Immu | 2012 |
Secondary soy allergy in children with birch pollen allergy may cause both chronic and acute symptoms.
Topics: Adolescent; Betula; Child; Child, Preschool; Female; Food Hypersensitivity; Glycine max; Humans; Mal | 2012 |
Monosensitization and polysensitization in allergic rhinitis.
Topics: Adult; Allergens; Animals; Asthma; Betula; Cohort Studies; Cross-Sectional Studies; Cupressus; Femal | 2011 |
STAT5 in human basophils: IL-3 is required for its FcεRI-mediated phosphorylation.
Topics: Adolescent; Adult; Basophils; Betula; Child; Female; Flow Cytometry; Humans; Inflammation; Interleuk | 2012 |
CD300a is expressed on human basophils and seems to inhibit IgE/FcεRI-dependent anaphylactic degranulation.
Topics: Adolescent; Adult; Anaphylaxis; Antibodies, Monoclonal; Antigens, CD; Basophils; Betula; Cell Degran | 2012 |
The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge.
Topics: Administration, Oral; Adult; Allergens; Asthma; Betula; Female; Food Hypersensitivity; Humans; Hyper | 2012 |
Clinical relevance of IgE to recombinant Gly m 4 in the diagnosis of adult soybean allergy.
Topics: Adult; Antigens, Plant; Betula; Cross Reactions; Female; Food Hypersensitivity; Glycine max; Humans; | 2012 |
Are anti-Phl p 12 IgE levels predictive of oral allergy syndrome in profilin hypersensitive patients?
Topics: Adult; Aged; Antigens, Plant; Betula; Cross Reactions; Female; Food Hypersensitivity; Humans; Immuno | 2011 |
Allergic asthmatics show divergent lipid mediator profiles from healthy controls both at baseline and following birch pollen provocation.
Topics: Adult; Allergens; Arachidonate 15-Lipoxygenase; Asthma; Betula; Bronchial Provocation Tests; Broncho | 2012 |
Systemic up-regulation of TLR4 causes lipopolysaccharide-induced augmentation of nasal cytokine release in allergic rhinitis.
Topics: Allergens; Betula; Bone Marrow; Cytokines; Humans; Leukocytes; Lipopolysaccharides; Nasal Lavage Flu | 2012 |
Perinatal maternal administration of Lactobacillus paracasei NCC 2461 prevents allergic inflammation in a mouse model of birch pollen allergy.
Topics: Animals; Antigens, Plant; Betula; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Femal | 2012 |
Age-dependent sensitization to the 7S-vicilin-like protein Cor a 11 from hazelnut (Corylus avellana) in a birch-endemic region.
Topics: Adolescent; Adult; Age Factors; Allergens; Belgium; Betula; Child; Corylus; Dermatitis, Atopic; Fema | 2012 |
Reactions of airway epithelial cells to birch pollen grains previously exposed to in situ atmospheric Pb concentrations: a preliminary assay of allergenicity.
Topics: Air Pollutants; Allergens; Antigens, Plant; Betula; Cell Line; France; Humans; Interleukin-5; Kineti | 2012 |
Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Topics: Administration, Oral; Adult; Antigens, Plant; Betula; Cytokines; Epitopes; Female; Forkhead Transcri | 2013 |
Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Topics: Adult; Allergens; Antigens, Plant; Betula; Binding, Competitive; Cytokines; Desensitization, Immunol | 2012 |
Dietary intervention for oral allergy syndrome as a treatment in orofacial granulomatosis: a new approach?
Topics: Adolescent; Adult; Aged; Ambrosia; Artemisia; Betula; Child; Child, Preschool; Crohn Disease; Cross | 2013 |
Influence of meteorological parameters and air pollution on hourly fluctuation of birch (Betula L.) and ash (Fraxinus L.) airborne pollen.
Topics: Air Pollution; Allergens; Betula; Circadian Rhythm; Environmental Monitoring; Fraxinus; Humans; Poll | 2012 |
Eosinophilic gastrointestinal disease suggestive of pathogenesis-related class 10 (PR-10) protein allergy resolved after immunotherapy.
Topics: Betula; Child; Cross Reactions; Enteritis; Eosinophilia; Eosinophils; Food Hypersensitivity; Gastrit | 2013 |
Birch-pollen sensitization in an area without atmospheric birch pollens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibody Specificity; Betula; Cedrus; Child; Child, Pres | 2002 |
Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization.
Topics: Adolescent; Adult; Aged; Allergens; Antibody Specificity; Antigens, Plant; Asthma; Betula; Calcium-B | 2002 |
Responses in the start of Betula (birch) pollen seasons to recent changes in spring temperatures across Europe.
Topics: Betula; Climate; Europe; Greenhouse Effect; Humans; Pollen; Rhinitis, Allergic, Seasonal; Seasons; T | 2002 |
Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1- related PR-10 protein in soybean, SAM22.
Topics: Allergens; Anaphylaxis; Antigens, Plant; Betula; Cross Reactions; Female; Food Hypersensitivity; His | 2002 |
Increased expression of Vascular Endothelial Growth Factor-A in seasonal allergic rhinitis.
Topics: Betula; Databases, Genetic; Endothelial Growth Factors; Humans; Nasal Lavage Fluid; Oligonucleotide | 2002 |
[Evolution of pollinization in France (2002)].
Topics: Air; Betula; France; Humans; Meteorological Concepts; Poaceae; Pollen; Retrospective Studies; Rhinit | 2003 |
[Pollen counts and allergies in Burgundy: profile and perspectives].
Topics: Adolescent; Adult; Air; Allergens; Asthma; Betula; Child; Conjunctivitis, Allergic; Environmental Mo | 2003 |
Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis.
Topics: Administration, Inhalation; Adult; Allergens; Anti-Allergic Agents; Betula; Biomarkers; Chemokines, | 2003 |
In vitro and in vivo allergenicity of recombinant Bet v 1 compared to the reactivity of natural birch pollen extract.
Topics: Adult; Allergens; Antigens, Plant; Betula; Female; Humans; Immunoglobulin E; Male; Nasal Provocation | 2003 |
The results of treatment of birch, oak and elm allergy with single annual injection of emulsified extract. VII.
Topics: Betula; Betulaceae; Humans; Hypersensitivity; Hyperthermia, Induced; Rhinitis, Allergic, Seasonal | 1959 |
Primary sensitization to sweet bell pepper pollen in greenhouse workers with occupational allergy.
Topics: Agricultural Workers' Diseases; Allergens; Antibody Specificity; Artemisia; Betula; Capsicum; Cross | 2003 |
White birch.
Topics: Allergens; Asthma; Betula; Humans; Plant Proteins; Pollen; Rhinitis, Allergic, Seasonal | 2003 |
Allergen-mediated modulation of CD23 expression is interferon-gamma and interleukin-10 dependent in allergic and non-allergic individuals.
Topics: Adult; Allergens; B-Lymphocytes; Betula; Cells, Cultured; Conjunctivitis, Allergic; Down-Regulation; | 2003 |
Cytokine production in peripheral blood cells during and outside the pollen season in birch-allergic patients and non-allergic controls.
Topics: Adult; Betula; Case-Control Studies; CD4-Positive T-Lymphocytes; Cytokines; Eosinophils; Female; Gra | 2004 |
[The influence of birch pollen on adenoid hypertrophy in children with seasonal allergic rhinitis].
Topics: Adenoids; Allergens; Betula; Child; Child, Preschool; Female; Humans; Hypertrophy; Male; Pollen; Rhi | 2003 |
No decrease of birch pollen specific IgA and IgG in nasal fluids from cortisone treated patients with intermittent allergic rhinitis.
Topics: Allergens; Antigens, Plant; Betula; Cortisone; Humans; Immunoglobulin A; Immunoglobulin G; Nasal Muc | 2004 |
Acoustic rhinometry in the assessment of adenoid hypertrophy in allergic children.
Topics: Adenoidectomy; Adenoids; Allergens; Betula; Child; Child, Preschool; Endoscopy; Evaluation Studies a | 2004 |
A role for neutrophils in intermittent allergic rhinitis.
Topics: Adolescent; Adult; Albumins; Allergens; Betula; Female; Humans; Male; Middle Aged; Nasal Lavage Flui | 2004 |
Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season.
Topics: Adult; Allergens; Betula; Cell Division; Cells, Cultured; Cytokines; Humans; Immune Tolerance; Inter | 2004 |
Allergy to jackfruit: a novel example of Bet v 1-related food allergy.
Topics: Adult; Allergens; Antigens, Plant; Artocarpus; Betula; Cross Reactions; Double-Blind Method; Female; | 2004 |
Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients.
Topics: Adult; Age Factors; Aged; Albuterol; Allergens; Ambrosia; Asthma; Betula; Bronchodilator Agents; Fem | 2004 |
Comparison of Alnus, Corylus and Betula pollen counts in Lublin (Poland) and Skien (Norway).
Topics: Alnus; Betula; Corylus; Environmental Monitoring; Humans; Norway; Poland; Pollen; Rhinitis, Allergic | 2004 |
Diagnostic value of birch recombinant allergens (rBet v 1, profilin rBet v 2) in children with pollen-related food allergy.
Topics: Adolescent; Allergens; Antigens, Plant; Asthma; Betula; Child; Child, Preschool; Contractile Protein | 2004 |
Bilateral nasal allergen provocation monitored with acoustic rhinometry. Assessment of both nasal passages and the side reacting with greater congestion: relation to the nasal cycle.
Topics: Adolescent; Adult; Allergens; Betula; Female; Humans; Male; Nasal Mucosa; Nasal Provocation Tests; P | 2005 |
Low levels of CC16 in nasal fluid of children with birch pollen-induced rhinitis.
Topics: Adolescent; Betula; Case-Control Studies; Child; Eosinophil Cationic Protein; Eosinophils; Female; H | 2005 |
Relationship between Bet v 1 and Bet v 2 specific IgE and food allergy in children with grass pollen respiratory allergy.
Topics: Allergens; Antigens, Plant; Betula; Child; Female; Food Hypersensitivity; Humans; Immunoglobulin E; | 2005 |
[A case of birch pollen-related food allergy syndrome].
Topics: Adolescent; Betula; Female; Food Hypersensitivity; Humans; Rhinitis, Allergic, Seasonal | 2005 |
Seasonal non-allergic rhinitis (SNAR)--a new disease entity? A clinical and immunological comparison between SNAR, seasonal allergic rhinitis and persistent non-allergic rhinitis.
Topics: Adolescent; Adult; Aged; Antibodies; Betula; Conjunctivitis; Cough; Female; Histamine H1 Antagonists | 2005 |
Birch pollen-related food allergy to legumes: identification and characterization of the Bet v 1 homologue in mungbean (Vigna radiata), Vig r 1.
Topics: Allergens; Amino Acid Sequence; Antigens, Plant; Betula; Circular Dichroism; Cloning, Molecular; Cro | 2005 |
[Anaphylactic reaction to soy drink in three patients with birch pollen allergy].
Topics: Anaphylaxis; Betula; Comorbidity; Cross Reactions; Female; Food Hypersensitivity; Humans; Immunoglob | 2005 |
Circulating eosinophils in asthma, allergic rhinitis, and atopic dermatitis lack morphological signs of degranulation.
Topics: Adolescent; Adult; Aged; Asthma; Betula; Cell Degranulation; Churg-Strauss Syndrome; Cytoplasmic Gra | 2005 |
Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children.
Topics: Administration, Sublingual; Adolescent; Allergens; Antibody Specificity; Antigens, Dermatophagoides; | 2006 |
Immunoglobulin G4-antibodies to rBet v 1 and risk of sensitization and atopic disease in the child.
Topics: Air Pollutants; Allergens; Betula; Chi-Square Distribution; Child, Preschool; Conjunctivitis, Allerg | 2005 |
The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice.
Topics: Administration, Intranasal; Allergens; Animals; Betula; Desensitization, Immunologic; Disease Models | 2006 |
Immunological characteristics of subjects with asymptomatic skin sensitization to birch and grass pollen.
Topics: Adult; Allergens; Betula; Betulaceae; CD4-Positive T-Lymphocytes; Cell Proliferation; Cells, Culture | 2006 |
Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy.
Topics: Allergens; Animals; Antigens, Plant; Betula; Drug Carriers; Female; Mice; Mice, Inbred BALB C; Nanos | 2006 |
A network-based analysis of allergen-challenged CD4+ T cells from patients with allergic rhinitis.
Topics: Adolescent; Adult; Algorithms; Allergens; Betula; CD4-Positive T-Lymphocytes; Cell Proliferation; Da | 2006 |
Airborne pollen concentrations and the incidence of allergic asthma and rhinoconjunctivitis in northern Italy from 1992 to 2003.
Topics: Adult; Ambrosia; Animals; Animals, Domestic; Asthma; Betula; Conjunctivitis, Allergic; Female; Human | 2007 |
An observational study on outgrowing food allergy during non-birch pollen-specific, subcutaneous immunotherapy.
Topics: Adult; Allergens; Betula; Cross Reactions; Desensitization, Immunologic; Female; Food Hypersensitivi | 2007 |
Grass pollen symptoms interfere with the recollection of birch pollen symptoms - a prospective study of suspected, asymptomatic skin sensitization.
Topics: Adolescent; Adult; Antigens, Plant; Betula; Denmark; Female; Humans; Male; Middle Aged; Poaceae; Pol | 2007 |
Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy.
Topics: Allergens; Allergoids; Animals; Antigens, Plant; Betula; Cell Line; Cells, Cultured; Dendritic Cells | 2007 |
The influence of birch pollination on the adenoid size in children with intermittent allergic rhinitis.
Topics: Adenoids; Betula; Child; Child, Preschool; Dermatitis, Atopic; Female; Health Surveys; Humans; Infan | 2007 |
The long-range transport of birch (Betula) pollen from Poland and Germany causes significant pre-season concentrations in Denmark.
Topics: Air Pollution; Betula; Denmark; Forecasting; Germany; Humans; Poland; Pollen; Rhinitis, Allergic, Se | 2007 |
Incidence of Betulaceae pollen and pollinosis in Zagreb, Croatia, 2002-2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Allergens; Alnus; Betula; Betulaceae; Coryl | 2007 |
Year-to-year variation in release of Bet v 1 allergen from birch pollen: evidence for geographical differences between West and South Germany.
Topics: Adult; Allergens; Antigens, Plant; Betula; Female; Follow-Up Studies; Geography; Germany; Humans; Ma | 2008 |
Short-term effect of pollen exposure on antiallergic drug consumption.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Allergic Agents; Antigens, Plant; Betula; Child; Child, P | 2007 |
The role of CCL22/macrophage-derived chemokine in allergic rhinitis.
Topics: Antigens, CD; Betula; Cell Movement; Chemokine CCL22; Chemokines; Dendritic Cells; Enzyme-Linked Imm | 2007 |
Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Topics: Adolescent; Adult; Aged; Allergens; Animals; Antibody Specificity; Basophils; Betula; Desensitizatio | 2008 |
Factors that determine the severity of Betula spp. pollen seasons in Poland (Poznań and Krakow) and the United Kingdom (Worcester and London).
Topics: Allergens; Betula; Climate; Humans; Meteorological Concepts; Poland; Pollen; Rhinitis, Allergic, Sea | 2008 |
Correlations between alder specific IgE and alder-related tree pollen specific IgE by RAST method.
Topics: Allergens; Alnus; Antigens, Plant; Betula; Epitopes; Humans; Immunoglobulin E; Japan; Molecular Mimi | 2008 |
Protease activity of allergenic pollen of cedar, cypress, juniper, birch and ragweed.
Topics: Ambrosia; Antigens, Plant; Betula; Cryptomeria; Cupressus; Cysteine Endopeptidases; Humans; Japan; J | 2008 |
Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
Topics: Adolescent; Adult; Aged; Allergens; Antigens, Plant; Betula; Calcium-Binding Proteins; Desensitizati | 2008 |
Use of phenological and pollen-production data for interpreting atmospheric birch pollen curves.
Topics: Allergens; Betula; Humans; Pollen; Rhinitis, Allergic, Seasonal; Seasons; Spain; Temperature | 2007 |
Comprehensive evaluation of genetic variation in S100A7 suggests an association with the occurrence of allergic rhinitis.
Topics: Adult; Aged; Allergens; Antigens, Plant; Betula; Calcium-Binding Proteins; Female; Gene Frequency; G | 2008 |
Predictive value of the sulfidoleukotriene release assay in oral allergy syndrome to celery, hazelnut, and carrot.
Topics: Adolescent; Adult; Apium; Basophils; Betula; Corylus; Daucus carota; Enzyme-Linked Immunosorbent Ass | 2008 |
Air pollutants enhance rhinoconjunctivitis symptoms in pollen-allergic individuals.
Topics: Adult; Air Pollutants; Allergens; Betula; Conjunctivitis, Allergic; Environmental Exposure; Female; | 2001 |
Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System.
Topics: Adolescent; Adult; Allergens; Antibody Specificity; Betula; Child; Child Welfare; Contractile Protei | 2002 |